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Introduction
Hypertension is an important risk factor for fatal and non-fatal cardiovascular 
events. After age and gender, blood pressure (BP) level is the most accurate 
predictor of life expectancy.1 Worldwide hypertension affects millions of 
people. Not surprisingly, indirect BP measurement is one of the most frequently 
performed health care procedures.1,2 However, it is one of the measurements 
performed most inaccurately.3
Blood pressure measurement techniques
Indirect BP measurement has developed revolutionary over the past two 
centuries. In the 19th and 20th century a vast amount of different devices was 
developed.4 In 1896 the Italian physician Scipione Riva Rocci introduced the 
use of an occluding arm cuff allowing the measurement of systolic pressure. 
The Russian surgeon Nicolai Sergeivich Korotkoff discovered the auscultatory 
method of systolic and diastolic BP measurement in 1905.4,5 Technological 
progress in the twentieth century has resulted in the development of the 
automated oscillometric measurement of BP.6 When pressure in a cuff was 
lowered from above systolic to below diastolic BP, oscillations in pressure 
were observed.7  The point where  oscillations are maximal has been shown to 
coincide with the mean arterial pressure. Using the automated oscillometric 
technique, it has become relatively simple to measure BP. Hypertensive patients 
or other interested individuals can easily measure their BP outside the clinical 
setting (self-measurement). The market for automated oscillometric devices is 
rapidly growing and these devices increasingly replace the use of the mercury 
sphygmomanometer. A variety of automated devices can be acquired through 
the Internet8 or bought at several shops.
For clinical BP measurement readings taken by a trained health care provider 
using a mercury sphygmomanometer and auscultation of Korotkoff sounds, 
have always been the gold standard. When BP was identified as an important 
cardiovascular risk factor in early prospective studies, like the Framingham 
study, it was measured with the mercury sphygmomanometer. However, BP 
measurements performed at home showed that office measurements may lead 
to misclassification of large numbers of normotensive individuals as hypertensive 
(white-coat hypertension).3,9 More recently, the opposite was also observed, 
namely a normal BP in the office with a higher BP at home (so called: 'masked 
hypertension').3,10  These two clinical situations can be explained by a number of 
factors: inaccuracy in the BP measurement, doctor related errors like terminal 
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digit preference, differences in the devices used an the inherent biological 
variability of BP.3,11 Concern exists about the accuracy of the oscillometric 
method. With the oscillometric technique systolic and diastolic BP are not 
actually measured, but are determined using an algorithm. These algorithms 
differ among devices and the contents of these algorithms are kept secret 
by the manufacturers. Thus, whereas mercury sphygmomanometers have been 
comparable concerning design and hence accuracy, the accuracy of different 
oscillometric devices can be expected to vary substantially. 
Before automated devices can substitute the mercury sphygmomanometer, they 
should be tested for their accuracy. For this purpose the British Hypertension 
Society (BHS), the European Society of Hypertension and the Association for 
the Advancement of Medical Instrumentation (AAMI) have each issued their 
own validation protocol.12-16 Because of the importance of BP measurement in 
hypertension management we investigated the accuracy of several automated 
oscillometric BP measuring devices. 
Drug adherence in hypertension treatment
Despite the availability of effective drugs to treat hypertension, about two 
third of  patients with hypertension in the United States are either untreated or 
undertreated.17,18 In almost one out of two patients BP remains too high despite 
treatment.18 One of the reasons for this is insufficient drug adherence. 
Drug adherence can be expected to decrease over time, because hypertension 
is largely an asymptomatic condition. Indeed the percentage of patients with 
hypertension that continued treatment for ten years was shown to be only 
39%. Twenty-two percent of patients temporarily discontinued treatment (drug 
holidays) and 39% of patients discontinued permanently.19 
The effect of different interventions to increase the level of adherence has 
been shown to be limited.20,21 The absence of a gold standard method to 
measure sufficient drug adherence, is a problem.22 The judgement of the 
physician has been shown to be inaccurate and many patients will not admit 
their non-adherence.22 Counting the remaining tablets after a treatment period, 
is frequently used in clinical trials for measuring drug adherence, but is known 
to be inaccurate. A promising technique known as electronic Medication Event 
Monitoring System (MEMS), was introduced in 1987. Electronic recording of date 
and time of each opening of a pill box, can help to monitor drug adherence. 
Unfortunately, also with this technique patients can mislead the investigator by 
throwing away medication. Truly objective methods that measure actual drug 
intake are still not available. Drug intake can be demonstrated by measuring 
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the amount of a chemical marker which is added to the drug a patient has to 
take.22 The ideal marker should have a long half life and has to be safe in the 
amounts administered. Preferably the marker is biologically inactive and is not 
metabolised. The anion bromide could be such a marker. The utility of bromide 
as a method to assess drug adherence and the application of this technique in 
clinical practice was examined as part of this thesis. 
Aim of the thesis
The aim of part I of this thesis was to study the accuracy of different 
automated oscillometric BP measuring devices as an alternative to the mercury 
sphygmomanometer. First, the current validation protocols were critically 
evaluated. Then the accuracy of two different oscillometric BP measuring 
devices, one measuring at the upper-arm and one at the wrist, was tested. 
The influence of the BP level on the accuracy of oscillometric BP measuring 
devices was further investigated. Finally a general overview on oscillometric 
BP devices is given.The aim of part II of this thesis was to study the use of the 
chemical marker bromide to measure drug adherence in healthy volunteers and 
hypertensive patients. The results were compared to other methods available 
to estimate drug adherence.
Chapter 1
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Chapter 2.1
Abstract
Objective To show that different methods of data analysis affect the grading 
that blood pressure measuring devices achieve according to the British 
Hypertension Society (BHS)-protocol.
Methods Based on the somewhat unclear description of the exact method of 
data analysis in the BHS-protocol four different methods can be discerned. The 
effect on the grading-results is calculated for these four different options.
Results and Conclusions It is shown that using these four different options 
the achieved grade can range for diastolic blood pressure from C (option 1) to 
almost A (option 4) and for systolic blood pressure from D (option 1) to B (option 
4). Different researchers may well have used different methods. Option 1 is the 
method that should be used. Also it is stated that the systematic error and the 
standard deviation of differences (SDD) are measures that give more insight to 
describe a device’s performance. Calculating the grades after correction for 
the systematic error shows its influence and that of the SDD on the reported 
accuracy of a blood pressure measuring device. 
Influence of method of data analysis
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Introduction
Different methods of data analysis affect the grading that blood pressure 
measuring devices achieve according to the British Hypertension Society (BHS) 
protocol. As a consequence of the somewhat unclear description of the method 
of analysis in the BHS-protocol, it is to be feared that different investigators 
have used different methods of analysis in their validation studies with 
unmistakable effects on the results of these studies. Moreover, the grading 
system of the BHS-protocol does not differentiate between the influence of the 
systematic error and the standard deviation of differences of a blood pressure 
measuring device on its accuracy. We describe a method to distinguish between 
these two factors. 
One of the most frequently used protocols to test the accuracy of automatic 
blood pressure measuring devices is the BHS-protocol.1 In phase IV, sequential 
blood pressure (BP) measurements are carried out in 85 subjects, as shown in 
Figure 1.
Observer 1
Device (Observer 3)
Observer 2
BP 1
BP 1
BP 2
BP 3
BP 3
BP 4
BP 5
BP 5
BP 6
BP 7
BP 7
Figure 1. Sequential blood pressure measurements carried out in 85 subjects
Methods
Observers 1 and 2 measure  BP  simultaneously  using  a mercury sphygmo-
manometer (see Figure 1). For the analysis, absolute differences between 
device- and observer-measurements and, subsequently the percentage of 
differences ≤ 5, ≤ 10 and ≤ 15 mmHg are calculated. Based on these percentages, 
a grade is given (Table 1). 
The differences between device- and observer-measurements should be 
calculated as follows: 'To compare one observer and test instrument, first 
analyse the data on 85 subjects using the pairs BP1 versus BP2, BP3 versus 
BP4, BP5 versus BP6. Then similarly analyse the pairs BP2 versus BP3, BP4 
versus BP5, BP6 versus BP7. The result most favourable for the test device is 
selected'.1 This paragraph from the BHS-protocol (1993) caused a great deal of 
concern, because how the precise analysis should be carried out is not clear. 
Four possible options will be explained, using a fictitious example (Figure 2).
24
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Option 1
For all 85 subjects, the differences BP1-BP2, BP3-BP4, BP5-BP6 are calculated 
(thus for observer 1: 3, 4, 3 for patient 1 and 4, 10, 12 for patient 2). One grade 
is therefore calculated for each observer. The same is done using the observer-
measurements after each device-measurement, i.e. BP2-BP3, BP4-BP5, BP6-
BP7 (example: 1, 8, 5 and 8, 6, 8 for observer 1 and 5, 2, 5 and 6, 4, 10 for 
observer 2). This leads to a grade for each observer. From the four grades from 
observers 1 and 2, the best is chosen. 
Option 2
The three differences obtained by calculating BP1-BP2, BP3-BP4, BP5-BP6 
for one patient (example: 3, 4, 3 for patient 1), are compared to the three 
calculated by BP2-BP3, BP4-BP5, BP6-BP7 (example: 1, 8, 5 for patient 1). From 
   
                                Absolute difference between standard and 
 test device (mmHg)
Grade ≤ 5 ≤ 10 ≤ 15
Cumulative percentages
A 60 85 95
B 50 75 90
C 40 65 85
D                      Worse than C  
To achieve a grade A, all percentages must be ≥ those in Table 1. Idem grade B and C. 
Table 1. British Hypertension Society grading criteria for sequential measurements
Figure 2. Examples of systolic (diastolic) pressure. 
Observer 1
Device (Observer 3)
Observer 2
128
130
125
126
130
122
130
124
127
132
132
3
5
1
5
4
8
8
2
3
3
5
5
Observer 1
Device (Observer 3)
Observer 2
118
114
122
130
128
120
126
124
114
122
124
4
8
8
6
10
8
6
4
12
10
8
10
Patient 1
Patient 2
Examples of systolic (diastolic) pressure.
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these two groups, one is chosen, based on how many times the differences ≤ 5, 
≤ 10 and ≤ 15 occur in each group (example: 3, 4, 3 for observer 1 and 5, 2, 5 
for observer 2). The same procedure applies to subjects 2-85, resulting in one 
grade for observer 1 and one for observer 2. Of these two, the best is chosen.
Option 3
The difference between the device-measurement and an observer-measurement 
taken before the device measurement, is compared with the difference 
between the same device-measurement and an observer-measurement taken 
after the device-measurement (BP1-BP2 versus BP2-BP3; BP3-BP4 versus BP4-
BP5, BP5-BP6 versus BP6-BP7). For every device-measurement, the smallest 
of two differences is chosen (example: for observer 1: patient 1: 1, 4, 3 and 
patient 2: 4, 6, 8). This is done separately for both observers, leading to one 
grade for each observer. The best of these two is chosen.
Option 4 
Differences between each device-measurement and the four surrounding 
observer measurements are calculated (i.e. BP1-BP2, BP2-BP3, observer 1 and 
BP1-BP2, BP2-BP3, observer 2). The smallest of these four differences is chosen 
(example: patient 1: 1, 2, 3; patient 2: 4, 4, 8) resulting in one grade for 
systolic and one for diastolic pressure. 
The grades that can be calculated for an automated blood pressure measuring 
device tested by us, according to the BHS-protocol using the four different 
options, are presented in Table 2. The BHS-grading improves going from option 
1 to 4. A device with grade A or B for both diastolic and systolic blood pressure 
can be recommended for clinical use. According to option 1 the device certainly 
cannot be recommended for clinical use, according to option 4, it can almost. 
The option used clearly affects the final grading. Option 2 is sometimes unclear 
about which of the two groups of measurements has to be chosen, for example 
for observer 1, patient 2 we have to chose between 4, 10, 12 and 8, 6, 8. The 
first group of three means; once ≤ 5; twice ≤ 10, and 3 times ≤ 15, whereas the 
second group means 0 times ≤ 5; 3 times ≤ 10; 3 times ≤ 15. Which of the two 
groups should be chosen? We would have chosen the first group of three. 
From O’Brien’s group, we learnt that the correct method for analysis is Option 
1 (personal communication), but Jones et al. (personal communication) used 
Option 2 for their analysis.2 Our fear is that investigators use different analyses 
in their validation studies. 
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The accuracy of a blood pressure measuring device can be described using 
two parameters: the mean of differences (i.e. the systematic error) and 
the standard deviation (SD) of differences (SDD). The latter being the most 
important, because the systematic error can be corrected. Thus in our opinion, 
a device with a mean difference of 10±0.1 (SDD, mmHg) is superior to a device 
with 0.5±5 mmHg. In the BHS-grading the first device would have graded D, 
whereas the second would have achieved a grade A. Thus, the BHS grades do 
not give enough information about the blood pressure measuring qualities of a 
device. Calculating the grades before and after correction for the systematic 
error can help to distinguish the impact of the mean of differences and the 
SDD of a device on the final grading. To illustrate this we again calculated the 
grades for the automated blood pressure measuring device, using Option 1, 
after first correcting for the systematic error. For diastolic blood pressure, the 
grading improved from C to B (almost A) and for systolic blood pressure, from 
D to B (Table 2). 
Perhaps an adaptation of the BHS-protocol is required.
   
                                
   Diastolic        Systolic
 ≤ 5 ≤ 10 ≤ 15    Grade ≤ 5 ≤ 10 ≤ 15     Grade
Option 1 43 77 94 C 35 68 90 D
Option 2 48 79 95 C 41 71 89 C
Option 3 53 85 97 B 46 75 93 C
Option 4 58 86 97 B 49 77 94 C
Correction 59 88 97 B 51 88 96 B
Table 2. Grading results for diastolic and systolic blood pressure using different methods of analysis
Influence of method of data analysis
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Dear Sir, 
It was with interest that we read the recent article concerning the 'International 
Protocol', a newly proposed protocol for the validation of automated blood 
pressure measuring devices.1 The objective of this new protocol was to 
simplify the most widely used protocols currently available, namely the British 
Hypertension Society (BHS) protocol 1993 and the protocol of the Association 
for the Advancement of Medical Instrumentation (AAMI). This has principally 
been achieved by eliminating phases 1 to 3 of the BHS-protocol, by decreasing 
the required number of subjects from 85 to 33 and by relaxing the recruitment 
of subjects in high and low blood pressure ranges. The 'International Protocol' 
is two-phased, making it possible to eliminate hopeless devices at an early 
stage. 
Despite these obvious improvements we would like to make some critical 
remarks. In the 'International Protocol' the A, B, C, D grading system has 
been replaced by a pass/fail system. This hinders direct comparison between 
validated devices. In our opinion the best measures to describe a device’s 
performance are the mean of differences and the standard deviation of 
differences (SDD). However these measures are not advocated by the current 
protocol. We find this strange not in the least because the minimum required 
number of differences <5, <10 and <15 mmHg (respectively 65, 80 and 95; Table 
2b of the 'International Protocol') are originally based on a normal distribution 
with a mean error of 0 mmHg and a standard deviation of approximately 5 
mmHg. 
It is also stated that a large mean difference is usually accompanied with 
a greater standard deviation of differences; i.e. the standard deviation 
increases with error.1 Using the same validation studies that formed the basis 
for the current changes in protocol we found a correlation coefficient of 0.19 
for systolic and -0.09 for diastolic blood pressure between mean error and 
standard deviation (see Figure 1).2–15 We therefore claim that it is possible for a 
device to show a large mean error with a relative small SDD. For such a device, 
simple correction of blood pressure readings with a constant factor would be 
appropriate.16 Applying the new 'International Protocol' would probably classify 
such a device as unsuitable at the early phase. We therefore recommend 
studying whether, on the basis of earlier validation reports, it is possible to 
restore and redefine the AAMI criteria. 
To test whether a device can accurately determine blood pressure in individuals 
a tertiary phase is introduced. In at least 22 out of 33 individuals two out 
of three differences should be <5 mmHg and a difference >5 mmHg for all 
Chapter 2.2
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three comparisons is allowed in no more than three subjects. Large blood 
pressure fluctuations over time in a few individuals could therefore result in 
the failure of an accurate device to pass. We support the idea of Shirasaki et 
al., to correct the SDD by subtracting the standard deviation of individual blood 
pressure variation from the overall standard deviation of differences.17 This 
would allow the user to adjust for the influence of intra-subject variability on 
the calculated accuracy of devices. 
Figure 1: Mean difference vs Standard deviation of 
different devices
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Figure 1. Mean difference versus standard deviation for different blood pressure measuring devices. 
Data are derived from the validation studies used to adapt the British Hypertension Society protocol.1,3–16 
For some devices more than one combination of mean error and standard deviation is used. For systolic 
blood pressure (SBP) a correlation coefficient of 0.19 and for diastolic blood pressure (DBP) of -0.09 is 
found. The vertical and horizontal lines are based on AAMI-criteria.
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Reply by Eoin O’Brien and Neil Atkins
Doctors Braam and Thien kindly acknowledge that the recently published 
International Protocol from the Working Group on Blood Pressure Monitoring 
of the European Society of Hypertension1 incorporates 'obvious improvements' 
over the earlier protocols of the British Hypertension Society (BHS)2 and the 
Association for the Advancement of Medical Instrumentation (AAMI).3 
However, they are critical of some aspects of the International Protocol. Their 
first concern is that replacement of the A–D grading system by a pass/fail system 
will hinder direct comparison between validated devices. The purpose of this 
approach was simply an acknowledgement of previous policy whereby devices 
gaining A and B grades according to the BHS protocol were recommended for 
clinical use, whereas those with C and D grades were not recommended.2 
Moreover, the tables in the International Protocol give full details of how the 
results are calculated and provide a more comprehensive means of device 
comparison than the former grading system. 
The use of the mean and standard deviation as the basis for assessing the 
performance of a device is recommended in the AAMI protocol.3 However, this 
approach is founded on the false assumption that device errors are normally 
distributed around the mean error. If the International Protocol had used a 
distribution based on a mean error of 0 mmHg and a standard deviation of 
5 mmHg, the requirements for <5 mmHg, <10 mmHg and <15 mmHg would 
have been 67, 94 and 99 measurements respectively. It is not mathematically 
possible to choose a simple mean and standard deviation that will give a 
distribution comparable to that in the protocol. If, for example, the AAMI limits 
of a mean error of 5 mmHg and a standard deviation of 8 mmHg were used, 
the <5 mmHg, <10 mmHg and <15 mmHg requirements would be 39, 70 and 
89 measurements. Even relating the standard deviation to the mean does not 
help. If, for example, the standard deviation were set so that at most 85% of the 
measurements would have an error of 10 mmHg, then depending on the mean 
difference, there would be an expected 5 mmHg limit of between 48 and 53% 
of the measurements and a restrictive 15 mmHg limit of between 97 and 98%. 
If values are chosen to ensure that the percentage of accurate measurements 
at a particular limit are reasonable then the requirements at lower limits will 
be too liberal whereas those at higher limits will be too restrictive. The use 
of non-parametric limits in the International Protocol is a valid, simple, and 
meaningful solution to this problem. 
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The International Protocol does not state that 'a large mean difference is usually 
accompanied with a greater standard deviation of differences'; what it does 
say is that 'standard deviations tend to increase with the error', which is quite 
different and indeed is supported by the data of Braam and Thien. It would not 
be appropriate to pass a device with a large mean error with a relatively small 
SDD as long as a simple constant correction factor was provided, because it 
would be totally impractical for manufacturers to sell devices and expect users 
to employ a correction factor. The onus should be on the manufacturer to do 
this prior to submitting the device for validation. The purpose of Phase 1 in the 
International Protocol is to detect such devices at an early stage so as not to 
dissipate resources on proceeding with a validation that is doomed to failure. 
The last issue of concern relates to the tertiary phase of the International 
Protocol in which a 'difference of >5 mmHg for all three comparisons is allowed 
in at most three subjects'. This has been introduced to allow specifically for the 
'large blood pressure fluctuations over time in a few individuals'. Based on the 
evidence of previous validation studies good devices will meet this criterion, 
and devices that do not are inaccurate by definition. It is accepted that studies 
based on statistical analyses can have Type I and Type II errors, and that a 
small percentage of devices (mostly marginal ones) will either incorrectly 
pass or fail a particular validation study. However, it is hoped that the much 
simplified International Protocol will result in the same devices being validated 
in a number of different centres thus reducing greatly the probability of such 
errors. 
Finally, the overall concern that the International Protocol may fail 'accurate' 
devices that have a 'few' shortcomings, may be countered by the argument that 
poor devices are being recommended on the basis of the current validation 
criteria being applied in the AAMI protocol.3 We are grateful to Braam and 
Thien for allowing us this opportunity to clarify these important aspects of the 
International Protocol. 
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Abstract
The accuracy of the Welch Allyn Vital Signs Monitor, a compact device for the 
oscillometric measurement of blood pressure, was determined according to 
the British Hypertension Society protocol. The monitor achieved a grade C for 
diastolic and a grade D for systolic blood pressure. The device is suitable for 
monitoring a patient, for example post-operatively, in the emergency department 
or during an intervention. The device cannot, however, be recommended for 
an exact determination of blood pressure when compared with the mercury 
sphygmomanometer. In an earlier validation report, the Welch Allyn Vital Signs 
Monitor achieved a grade A for both diastolic and systolic blood pressure. After 
adjusting for the difference in method of calculating the grades used in the two 
studies, there remained a considerable difference in grading results, for which 
no clear reason could be found. 
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Introduction
The market for automated blood pressure measuring devices is a rapidly 
growing one, devices for self-measurement being sold in vast quantities. The 
use of automated blood pressure measuring devices is increasing not only in 
the home, but also in the clinical setting. Mercury sphygmomanometers are 
currently still used in some hospitals, but with the inevitable banning in the 
near future of mercury because of environmental hazards, clinicians will 
be forced to look for alternatives.1–3 Aneroid devices have, when calibrated 
against mercury sphygmomanometers, been shown to perform adequately in 
the beginning but poorly after a period of clinical use.1,4 The introduction of 
aneroid devices will therefore mandate a verifying and stamping procedure 
at least every year.5 Automated blood pressure measuring devices could be an 
alternative, but only if they are accurate enough. They are, however, rather 
expensive. These devices should be tested for their accuracy before using them 
in clinical practice or at home and a number of protocols have been drawn up 
in order to do this. Of these, the protocols of the British Hypertension Society 
(BHS) and the Association for the Advancement of Medical Instrumentation 
(AAMI)6,7 are the most widely used. A great number of devices has so far been 
tested according to these protocols.8 Both protocols are quite elaborate so 
proposals have recently been made for their simplification.9 We used here the 
1993 BHS protocol to determine the accuracy of the Welch Allyn Vital Signs 
Monitor (VSM). 
Methods 
The Welch Allyn VSM 52000 series is a compact, portable, light-weight (2.5 kg) 
device for the oscillometric measurement of blood pressure. It can measure 
systolic pressures of between 60 and 250 mmHg, diastolic pressures of between 
30 and 160 mmHg and heart rates ranging from 40 to 200 beats per min. Blood 
pressure measurements (up to 99) can be stored and can also be printed out if 
required. The cuff pressure deflation occurs in steps of 8–10 mmHg. A number 
of hospitals in the Netherlands currently use this device in clinical practice.
British Hypertension Society protocol
The 1993 BHS protocol6 consists of five phases: (1) before-use device calibration, 
(2) in-use assessment, (3) after-use device calibration, (4) static device 
validation and (5) report of the evaluation. To test the Welch Allyn VSM, we 
followed these five phases of the protocol, having first made a few adaptations 
to some of the phases, as explained below. 
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Before-use device calibration 
In this phase, the performance of the device as a manometer is compared 
with that of a mercury sphygmomanometer. The device is connected to a 
mercury sphygmomanometer, which is in turn connected to another mercury 
sphygmomanometer. All three manometers are then connected to a cuff 
wrapped around a cylinder. Observer 1 reads a mercury sphygmomanometer, 
and observer 2 reads the device. A third observer calls out 'now' at certain 
pressures according to a table, and observers 1 and 2 read the pressures 
indicated by their respective devices. There should be five calls per deflation 
and six deflations per device. Twenty-eight out of the 30 measurements taken 
by observers 1 and 2 should differ no more than 3 mmHg. If the device does 
not pass phase 1, further testing is not performed. Because performing phase 1 
in this manner is relatively time-consuming, and because of the possible error 
that can occur when undertaking this phase in the manner described, we used a 
somewhat different approach. We used a device named the CuffLink (Dynatech, 
Carson City, Nevada, USA) to test the performance of the Welch Allyn VSM as 
a manometer.10 The CuffLink is linked to the Welch Allyn VSM and a mercury 
sphygmomanometer and subsequently generates pressures of between 0 and 
300 mmHg. The pressure measured by the VSM can then be compared with 
that measured simultaneously by the mercury sphygmomanometer. At least 30 
measurements are made. These two approaches are in essence the same. 
In-use assessment
The device is used for 1 month to assess its performance in daily practice. 
There should be at least 400 inflations per device, and problems encountered 
during this phase should be recorded.
After-use device calibration
During this phase, the procedure described in phase 1 is repeated to see 
whether there is any change in accuracy of the device as a manometer as a 
result of 1 month’s use in practice.
Device validation
The observers were first trained using the method described in the BHS 
protocol.6 Contrary to the BHS protocol, we used two observers, instead of 
three, both of whom were blinded to each other and to the device. Sequential 
same-arm measurements were then carried out in different subjects. The first 
blood pressure measurement was used to determine which blood pressure 
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category the subject belonged to. It has been reported that recruiting subjects 
with extremes of blood pressure blood is difficult9  so we adapted the required 
distribution into different blood pressure categories as previously proposed: 
for diastolic blood pressure, the distribution was one-third with a pressure 
less than 80 mmHg, one-third with a pressure between 80 and 100 mmHg, and 
one-third with one over 100 mmHg; for systolic blood pressure, one-third were 
placed in each of three categories – less than 130 mmHg, between 130 and 160 
mmHg and greater than 160 mmHg.9 
The subjects used in the systolic blood pressure group do not have to be the 
same subjects who are used for the diastolic blood pressure group. A subject 
can, for example, have a diastolic blood pressure of 110 mmHg and a systolic 
blood pressure of 150 mmHg, being allocated to the category with a diastolic 
blood pressure of 100 mmHg or above, but not to the systolic group of 130–160 
mmHg if this has already been filled. Thus, the groups for the two pressures 
are not necessarily composed of the same subjects, and it may be necessary 
to perform sequential measurements in more than 85 subjects before enough 
suitable individuals have been recruited to each blood pressure category. 
All the measurements were carried out with the subjects lying supine after at 
least 5 min rest. The Welch Allyn VSM and the mercury sphygmomanometer 
were connected to the same bladder and cuff, alternating measurements being 
made possible by the use of a T-tap, which prevented manual cuff changes 
having to be made after each reading. The arm circumference of each subject 
was determined to check whether it was appropriate for the cuff size. The two 
observers’ hearing was checked prior to the measurements. 
Analysis was carried out separately for each observer, each device receiving a 
grade A, B, C or D according to Table 1. 
  
   
   
                                
Absolute difference between standard and test device (mmHg)a
Grade  ≤ 5   ≤ 10              ≤ 15
Cumulative percentages
A  60   85  95
B  50   75  90
C  40   65  85
D                  Worse than C
aTo achieve a particular grade, all the percentages must be equal to or greater
than those in the table 
Table 1. Britsh Hypertension Society grading criteria for sequential measurements6
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To calculate a grade, the percentages of device measurements differing from 
those of the mercury sphygmomanometer by less than 5, 10 and 15 mmHg were 
calculated. The final grade was the best grade out of four (two from observer 
1 and two from observer 2).6 The same procedure is followed for both systolic 
and diastolic blood pressure. It is therefore possible that the best grade for 
systolic blood pressure is obtained with observer 1, whereas the best grade for 
diastolic blood pressure is obtained from observer 2. Only devices reaching a 
grade A or B for both systolic and diastolic blood pressure can be recommended 
for use in clinical practice. According to the AAMI criteria, the mean difference 
has to be 5 mmHg or less and the standard deviation of the differences 8 mmHg 
or less.7 The discrepancy between the two observers has to be such that 80% of 
the differences between observer 1 and 2 fall within 5 mmHg and 95% within 
10 mmHg.6 
Another method for visualizing the relation between the differences and the 
absolute blood pressure values has been developed by Bland and Altman.11 In 
this study, we also present Bland–Altman plots. 
Results
Phases 1–3
The Welch Allyn VSM passed the before- and after-use device calibrations 
without any problems. During the in use assessment, the device appeared to 
be very reliable and easy to use.
Device validation
Two observers were trained by an experienced clinician at our hospital. 
Sequential measurements were carried out on 123 subjects recruited from 
the out-patient clinic of the department of internal medicine at our centre. 
Patients with a cardiac arrhythmia were excluded from the measurements. 
The 123 subjects were arranged according to the sequence of measurements. 
Among these subjects, individuals were selected based on their diastolic and 
systolic (entry) blood pressure until a sufficient number had been recruited to 
each subgroup. The characteristics of the group of 85 subjects selected for the 
diastolic and the systolic blood pressure groups are as shown in Table 2. 
A total of 118 subjects had to be included in order to reach the right distribution 
of blood pressure level. The differences between the observers lay well within 
the acceptable range (Table 3).
The VSM achieved a grade C for diastolic and a grade D for systolic blood 
pressure measurement (Table 3). Also shown are the results for the different 
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blood pressure categories. It can be seen that the device becomes less accurate 
in the higher blood pressure categories (Table 3). 
Figures 1 and 2 show the results for diastolic and systolic blood pressure 
as Bland–Altman plots. For diastolic blood pressure, there was a significant 
correlation of r=0.44 (P<0.0001). There was no significant correlation for 
systolic blood pressure.
   
                                
 
    Diastolic blood  Systolic blood 
        pressure       pressure
    
Mean age±SD    51±16  48±18
Number of women (%)   52(61)  54(64)
Mean arm circumference±SD (cm)  27.6±3.1  27.4±3.2
Mean height±SD (cm)    170±10  170±9
Mean weight±SD (kg)    78±15  76±14
Table 2. The characteristics of the two groups of 85 subjects whose diastolic and systolic blood  
pressures, respectively, were used for grading. A total of 118 subjects participated (see text)
Table 3. Grading results for the Welch Allyn Vital Signs Monitor
Absolute difference between standard and test device (mmHg)
  n  ≤5 (%)   ≤10 (%) ≤15 (%)    Mean±SD (AAMI)a  
Difference between observers
DBP A 255  92 100 100 -0.4±2.8
SBP A 255  91 99 99 0.5±3.2
Final grade 
DBP C 255  43 77 94 5.3±6.7
SBP D 255  35 67 90 7.5±7.1
 Accuracy of the Welch Allyn Vital Signs Monitor for different blood pressure levels
Blood pressure <80/<130 mmHg   
DBP B 84  52 87 98 2.1±6.5
SBP C 84  46 77 96 5.9±6.0
Blood pressure 80-100/130-160 mmHg 
DBP C 87  45 77 95 6.6±5.5
SBP D 87  28 64 93 7.8±6.1
Blood pressure >100/>160 mmHg 
DBP D 84  31 67 89 7.3±7.0
SBD D 84  31 60 80 10.5±13.5
Method of Jones et al. 12,13
DBP C 255  48 79 95
SBP C 255  40 75 93
aCriteria for passing Association for the Advancement of Medical Instrumentation grading: mean 
difference <5 mmHg and standard deviation <8 mmHg (for both systolic (SBP) diastolic (DBP) blood 
pressure).7
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Diastolic blood pressure, observer 1 vs device
Mean diastolic blood pressure, (obs1+device)/2
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Figure 1. Bland–Altman plot for diastolic blood pressure showing absolute blood pressure versus 
difference between blood pressure measured by observer and device: n=255, r=0.44 (P<0.0001). Obs, 
observer. For further details see text.
Systolic blood pressure, observer 2 vs device
Mean systolic blood pressure, (obs2+device)/2
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Figure 2. Bland–Altman plot for systolic blood pressure showing absolute blood pressure versus 
difference between blood pressure measured by observer and device: n=255, r= not significant. Obs, 
observer. For further details see text.
Discussion
The Welch Allyn VSM appeared to be a reliable easy-to-use device. Jones et 
al. have also tested the Welch Allyn VSM, reporting a grade A for both systolic 
and diastolic blood pressure. Moreover, they found that this grading was not 
affected when the data were divided into low-, medium- and high-pressure 
categories, except for medium diastolic blood pressure (range 80–100 mmHg), 
for which the grading became a B.12
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The conclusion reached by Jones et al. was therefore that 'the monitor achieved 
the highest possible grade A, for both systolic and diastolic blood pressure and 
very few devices achieved such accuracy, which uniquely remained consistent 
over all blood pressure ranges'.12 
So how can this difference in results be explained? The method of data analysis 
influences the reported accuracy of automated blood pressure measuring 
devices13, and Jones et al. used a somewhat different method of calculating 
the grades from that used in the BHS protocol.5,13 Sequential measurements 
are carried out as indicated in Figure 3. Using an example (Figure 3), we will 
explain the difference in the method employed in the BHS-protocol and that 
used by Jones et al. These authors calculated the grades by comparing for 
patient 1 the three differences calculated from BP1 – BP2, BP3 – BP4 and BP5 
– BP6 (3, 4 and 3 in the example) with the three values BP2 – BP3, BP4 – BP5, 
BP6 – BP7 (1, 8 and 5 in our example). From these two sets of figures, one is 
chosen based on how many times the differences <5, <10 and <15 mmHg occur 
in each group (in this example, 3, 4 and 3 being chosen). The same is done for 
subjects 2 – 85, resulting in one grade for observer 1 and one for observer 2, 
the best of which is chosen. 
According to the BHS protocol, the following calculation should be performed. 
For all 85 subjects, the differences BP1 – BP2, BP3 – BP4 and BP5 – BP6 are 
calculated (giving, in our example, 3, 4 and 3 for observer 1, and 5, 8 and 3 for 
observer 2). Thus, one grade is calculated for each observer. The same is done 
using the observer measurements after each device measurement, i.e. BP2 
– BP3, BP4 – BP5 and BP6 – BP7 (in the example, 1, 8 and 5 for observer 1, and 5, 
2 and 5 for observer 2). This also leads to a grade being given to each observer. 
From the two grades for observer 1 and the two grades for observer 2, the best 
is chosen. If we had used Jones et al.’s method, the grading results would have 
been slightly better, as shown in Table 3, but we would still have been unable 
to reach a grade A for diastolic and systolic blood pressure in our study. 
We can find no explanation for the remaining difference in grading results: 
both investigations used sequential measurements as described in the BHS 
protocol, the inter-observer differences lay well within acceptable limits and 
were comparable in the two studies, and both studies employed well-trained 
observers to make the measurements. There have, to our knowledge, not 
been any validation studies involving conventional oscillometric devices using 
the BHS protocol that have compared the accuracy of the same device when 
used by different groups. Different investigators can apparently come up with 
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Based on our results, the Welch Allyn VSM cannot be regarded as a good 
substitute for the mercury sphygmomanometer. On the other hand, because 
of the relatively small standard deviation of the differences, the device is 
certainly suitable for monitoring a patient, for example post-operatively, during 
a stay in the emergency department or during an intervention. Because of its 
ability to detect blood pressure fluctuations over time in the same patient, 
the device is equipped to perform adequately the task its name suggests, that 
of monitoring the 'vital signs'. For the diagnosis, treatment and control of 
hypertensive patients, a more accurate automatic blood pressure measuring 
device is, however, needed.
Figure 3. Sequential measurements used in the 1993 British Hypertension Society protocol,  
with an example for systolic pressure
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different grading results for the same device, making the results of validation 
reports of individual research groups more difficult to interpret. 
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Abstract
Objective  To determine the accuracy of the Omron RX-M, a device measuring 
blood pressure oscillometrically at the wrist.
Methods  In 89 subjects (mean age 55 ± 14 years) blood pressure measurements 
at the wrist with the Omron RX-M were compared to sequential blood pressure 
measurements with a mercury sphygmomanometer at the (same) upper-arm 
and to simultaneous measurements with the Omron HEM-705 CP at the opposite 
arm. 
Measurements were analyzed according to the British Hypertension Society 
(BHS) - protocol 1993, to the protocol of the Association for the Advancement of 
Medical Instrumentation (AAMI) and (retrospectively) to the new 'International 
Protocol'. 
Results  Mean differences (± SD) between the measurements with the mercury 
sphygmomanometer and the Omron RX-M were – 7.5 ± 8.4 mmHg for diastolic 
blood pressure (DBP) and – 2.5 ± 12.2 mmHg for systolic blood pressure (SBP), 
thus not fulfilling the AAMI-criteria (≤5 ± 8). According to the BHS-criteria a 
grade D was achieved for both DBP and SBP. Compared to the Omron HEM 705 
CP results were – 6.3 ± 7.1 for DBP (grade D) and – 4.1 ± 12.7 for SBP (grade D). 
The Omron RX-M also failed to pass the new 'International Protocol' in phase 
1.
Conclusion  Although easy to use, based on this study the Omron RX-M can not 
be recommended to determine blood pressure accurately.
Omron RX-M
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Introduction
The market for automated blood pressure-measuring devices is a rapidly growing 
one. Over 11 million devices were sold worldwide in 2000.1 Self-measurement 
(home measurement) of blood pressure is becoming increasingly popular. 
Self-measurement could help to increase compliance to medical therapy and 
avoids the 'white-coat' effect. Ohkubo et al.2 showed that home blood pressure 
measurement was a stronger predictor of cardiovascular mortality than office 
blood pressure. However in order to interpret measurements correctly new 
reference values have to be defined.3 Also measurements should be reliable 
and the devices should be easy to operate.1 
A great number of blood pressure measuring devices for self-measurement of 
upper arm blood pressure so far have been validated.4 However there have 
been only a few reports concerning the accuracy of devices measuring blood 
pressure at the wrist. These devices have the advantage of easy applicability 
and small volume, making it possible to measure blood pressure in a variety 
of circumstances. A number of protocols have been drawn up to test the 
accuracy of blood pressure measuring devices. Of these protocols two have 
been extensively used, the British Hypertension Society (BHS) and the protocol 
of the Association for the Advancement of Medical Instrumentation (AAMI).5,6 
Only recently a newly developed protocol, named the 'International Protocol' 
has been added on behalf of the Working Group on Blood Pressure Monitoring of 
the European Society of Hypertension.7 In the present study we have still used 
the BHS-protocol (1993) as a directive to determine the accuracy of the Omron 
RX-M wrist blood pressure measuring device.
Methods
The Omron RX-M is a compact, light-weight (150 g) device, designed for 
measuring blood pressure oscillometrically at the wrist. It can measure blood 
pressures between 40–280 mmHg and heart rates between 40–200 beats/min. 
Up to 14 measurements can be stored. Wrist circumference should be between 
13.5–19.5 cm.
BHS-protocol (1993)5
The former BHS-protocol 1993 consists of five phases: (1) before-use device 
calibration; (2) in-use assessment; (3) after-use device calibration; (4) static 
device validation and (5) report of evaluation. 
To test the Omron RX-M the most important phase of this protocol, phase 4, 
was followed, after having made some adaptations that will be explained 
54
Chapter 2.4
below. In accordance with the new 'International Protocol' phases 1 to 3 have 
not been performed. These phases were mainly introduced to secure uniform 
manufacturer’s standards for production of devices.
Device validation
First a human observer trained by the method described in the BHS-protocol.5 
Contrary to the BHS-protocol we used one human observer instead of two 
performing sequential blood pressure measurements on the same arm as 
the test-device. The Omron HEM-705 CP was used as a second 'observer'. 
Simultaneous measurements on the opposite arm were performed using this 
device. The Omron HEM-705 CP has been shown to be a reliable and accurate 
blood pressure measuring device, achieving a grade 'A' and 'B' for diastolic and 
systolic blood pressure respectively in a previous validation report.4,8 It also 
passed the AAMI criteria.8 
Sequential same-arm measurements are carried out in different subjects. A 
total of 85 subjects for diastolic and systolic blood pressure are required. The 
first blood pressure measurement is used to determine which blood pressure 
category the subject belongs to. It has been mentioned before that recruiting 
subjects with blood pressures at the extremes of high and low blood pressure 
range is difficult.9 Therefore we adapted the required distribution into different 
blood pressure categories as previously proposed: for diastolic blood pressure 
the distribution has to be 1/3 <80 mmHg, 1/3 between 80–100 mmHg, and 1/3 
>100 mmHg and for systolic blood pressure, 1/3 <130 mmHg, 1/3 between 
130–160 mmHg and 1/3 >160 mmHg.8 These blood pressure ranges have now 
also been introduced in the 'International Protocol'.7 
The subjects used in the systolic blood pressure group are not necessarily the 
same subjects used in the diastolic blood pressure group. For example a subject 
can have a diastolic blood pressure of 110 mmHg and a systolic blood pressure 
of 150 mmHg and therefore can be used in the category with a diastolic blood 
pressure >100 mmHg, but the category with a systolic blood pressure between 
130–160 mmHg has already been filled. Thus the total group of subjects for 
diastolic and systolic blood pressures are not necessarily composed of the same 
subjects and it can be necessary to perform measurements in more than 85 
subjects before enough suitable subjects have been recruited for each blood 
pressure category. 
All measurements were carried out with the subjects supine after at least 5 min 
rest. Measurements with the Omron RX-M were done with the wrist at heart 
level. Sequential measurements were carried out according to the scheme 
Omron RX-M
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described in the BHS-protocol.5,10 Also simultaneous measurements with the 
Omron RX-M (wrist) and the Omron HEM-705 CP (opposite arm) were performed. 
Differences in blood pressure between left and right arm have been shown to 
be small.11 However in order to compensate for a possible systematic left/right 
difference in blood pressure for all subjects, the position of the wrist device at 
the left or right side was determined by chance.
The wrist circumference of each subject was determined to check whether it 
was appropriate for the cuff-size. Only subjects with a wrist circumference 
between 13.5–19.5 cm were selected. Six of 95 subjects were excluded 
because the wrist circumference was too large. Upper-arm circumference 
had to be between 22–32 cm. Analysis was carried out separately for observer 
I and 'II' (i.e., the Omron HEM-705 CP). Each device receives a grade A, B, 
C or D according to Table 1. To calculate a grade the percentages of device 
measurements differing from the mercury sphygmomanometer by 5, 10 and 
15 mmHg or less were calculated. The same procedure is followed for systolic 
and diastolic blood pressure. For the simultaneous measurements of the 
Omron RX-M and Omron HEM-705 CP the more stringent grading criteria of the 
BHS-protocol 1990 were used.12 Only devices reaching a grade A or B for both 
systolic and diastolic blood pressure can be recommended for use in clinical 
practice. According to the AAMI criteria the mean difference has to be 5 mmHg 
or less and the standard deviation of differences has to be 8 mmHg or less.6 
A method to visualize the dependency of the differences from the absolute 
blood pressure values is developed by Bland and Altman.13 In this study we also 
present Bland–Altman plots.
Results
                       
  Absolute difference between standard and test device (mmHg)*
Grade  ≤ 5   ≤ 10              ≤15
Cumulative percentages
1990  
A  80   90  95
B  65   85  95 
C  45   75  90
D                  Worse than C
1993
A  60   85  95
B  50   75  90
C  40   65  85
D                  Worse than C
Table 1. Britsh Hypertension Society grading criteria for simultaneous (upper part) and for sequential 
measurements (lower part) from the protocols 1990 and 19935,12
*To achieve a certain grade all percentages must be equal to or greater than those in 
the table.
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Results
The human observer was trained by an experienced clinician at our hospital. 
Mean difference (±SD) between observer and expert measurements in 18 
subjects (three measurements per subject) were – 0.2 (±2.2) mmHg for diastolic 
and 0.1 (±3.6) mmHg for systolic blood pressure. Subsequently, measurements
were carried out in 89 subjects mainly recruited from the outpatient clinic of 
the department of internal medicine. The characteristics of the 89 subjects are 
shown in Table 2. The distribution of the subjects over the predefined blood 
pressure levels is also shown in Table 2. 
As can be seen the predefined number of subjects with a systolic blood pressure 
below 130 mmHg was not reached. Based on the comparison between observer 
measurements and device measurements the Omron RX-M achieved a grade 
'D' for diastolic and 'D' for systolic blood pressure. Results are shown in Table 3 
and Figure 1. Grading results were unaffected by blood pressure level and by 
patient’s age. Based on the (sequential) measurements with the Omron HEM-705 
CP and the mercury sphygmomanometer at opposite arms, difference of blood 
pressure between left and right arm were shown to be small. With the mercury 
sphygmomanometer on the right arm, mean blood pressure difference was +2 
mmHg and – 2 mmHg for systolic and diastolic blood pressure, respectively and 
with the mercury sphygmomanometer on the left arm +1 mmHg and – 1 mmHg. 
Differences between measurements with the mercury sphygmomanometer and 
the Omron HEM-705 CP are shown in Table 3 and Figure 2. In comparison with 
the Omron HEM-705 CP the test device achieved a grade 'D' for diastolic and 'D' 
for systolic blood pressure (see Table 3 and Figure 3). 
Table 2. The characteristics of the group of 89 subjects whose diastolic and systolic blood pressure 
were used for grading and distribution over predefined blood pressure levels (see text).
Mean age ± SD                   55±13.7
Number of women (%)       49 (55)
Mean wrist circumference ± SD in cms     17±1.3 
Mean upper arm circumference ± SD in cms    29±2.8
                                
        Diastolic blood pressure (mmHg)     Systolic blood pressure (mmHg)
 <80 80-100 >100 <130 130-160 >160 
Wanted 29 29 28 28 29 28
Achieved 23 47 19 11 34 44
  
Omron RX-M
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We retrospectively followed the method of the recently published  'International 
Protocol'. The device would have been rejected in phase 1 of the protocol (see 
Table 3). Blood pressure measurements in 21 people would have been enough 
to reject the device in phase 1. 
Table 3. Grading results for the Omron RX-M
Absolute difference between standard and test device (mmHg)
  Grade n <5 <10 <15  Mean±SD (AAMI)*
 
Observer versus Omron RX-M 
 DBP D 267 37% 67% 83% -7.5±8.4
 SBP D 267 37% 65% 81% -2.5±12.2
Observer versus Omron HEM 705 CP
 DBP A 267 60% 85% 96% -1.3±7.6
 SBP C 267 42% 71% 88% 1.6±10.9
Omron HEM 705 CP vs Omron RX-M 
 DBP D 267 42% 72% 88% -6.3±7.1
 SBP D 267 29% 50% 78% -4.1±12.7
Observer versus Omron RX-M using International Protocol7 
Phase 1      Pass/Fail
 DBP  45 16 31 37 F
 SBP  45 17 29 38 F
Phase 2.1
 DBP  99 35 59 79 F
 SBP  99 32 61 78 F
Phase 2.2                      At least 2/3    0/3<5
 DBP  99 13 14  F
 SBP  99 14 12  F   
*Criteria for passing AAMI: mean difference <5 mmHg and standard deviation <8 mmHg 
(for both systolic and diastolic blood pressure).
Figure 1.  Bland–Altman plot for diastolic and systolic blood pressure showing absolute blood 
pressure versus difference between blood pressure measured by observer and wrist device 
(sequential measurements, same arm). Obs, observer; Vs, versus.
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Figure 2. Bland–Altman plot for diastolic and systolic blood pressure showing absolute blood pressure 
versus difference between blood pressure measured by observer and Omron HEM-705 CP (sequential 
measurements, opposite arm). Obs, observer; Vs, versus.
Figure 3. Bland–Altman plot for diastolic and systolic blood pressure showing absolute blood 
pressure versus difference between blood pressure measured by Omron HEM-705 CP and Omron RX-M 
(simultaneous measurements, opposite arms). Vs, versus.
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Discussion
The Omron RX-M proved to be an easy to use device. Less than 4% of 
measurements were erroneous. The Omron RX-M achieved a grade 'D' for 
systolic and diastolic blood pressure. These results were highly reproducible 
when using the Omron HEM-705 CP as a reference. This validation report is the 
first to use an independent oscillometric blood pressure measuring device as a 
reference standard. The Omron HEM-705 CP has previously been shown to be a 
reliable and accurate blood pressure measuring device, validated according to 
the BHS-protocol and AAMI.4,8 
A  number of wrist blood pressure measuring devices have been tested.4 But most 
of the devices have shown poor results. The Omron RX [HEM-608] achieved a 
grade 'B' for diastolic and systolic blood pressure in a previous validation report, 
but failed to achieve the AAMI criteria due to the large standard deviation of 
differences (nine for diastolic and systolic blood pressure).14 The differences in 
grading results between the previous study and ours may in part be explained 
by a difference in method of data analysis as has been shown previously for the 
validation of the Welch Allyn Vital Signs Monitor.9,15 
One more fundamental question is whether blood pressures measured at the 
radial artery and brachial artery are suitable for comparison. O’Rourke et al.16, 
have shown that systolic blood pressure increases and diastolic blood pressure 
decreases (and hence pulse pressure increases) moving more distal from the 
ascending aorta. 
Therefore a moderate difference between blood pressure measured at the 
upper arm and wrist can be expected. However mean blood pressure will be 
the same at these two sites and most oscillometric devices use algorithms to 
extrapolate systolic and diastolic blood pressure from this mean value. 
In this study only one human observer was used instead of two. This leads to 
the potential danger that errors in blood pressure measurement by the human 
observer may greatly influence grading results. However the observer was well 
trained and with the Omron HEM-705 CP as a second independent 'observer' 
the same grading results were obtained. As can be seen in Table 2 the desired 
distribution of subjects over the blood pressure categories was not reached: 
especially the category of systolic blood pressure <130 mmHg could not be 
filled. 
Using the 'International Protocol' we would have rejected the Omron RX-M in 
an early phase. The new protocol therefore seems to offer us the advantage 
of eliminating inaccurate devices at an early stage, thereby saving money, 
resources and time. 
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We conclude that based on our results the Omron RX-M is not able to determine 
blood pressures accurately. A more accurate wrist blood pressure measuring 
device has to be awaited.
Omron RX-M
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Chapter 2.5
Is the accuracy of blood pressure measuring devices 
underestimated at increasing blood pressure levels?
Blood Pressure Monitoring 2005;10:283-289.
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Background  In validation studies reporting on the accuracy of blood pressure 
measuring devices (ambulatory and non-ambulatory systems), it is frequently 
stated that the accuracy of blood pressure devices seems to decrease at 
increasing blood pressure levels. This has been shown for several ambulatory 
devices in the past. Whether more recently validated devices are less accurate 
at increasing blood pressure levels is unknown, however. 
Objectives  We therefore retrospectively searched the literature for studies 
performed between 1993 and 2003, reporting on the accuracy of blood 
pressure measuring devices over different blood pressure levels. When needed, 
additional information from the authors was requested. 
Methods  In total, 30 studies were selected. Of these, the studies reporting 
on the accuracy of 13 different ambulatory and nine different non-ambulatory 
devices were useful. For both ambulatory and non-ambulatory devices, accuracy 
appeared to decrease at increasing blood pressure levels. This was particularly 
shown for systolic blood pressure. 
Results  We speculate whether this finding is due to the oscillometric method 
of blood pressure measurement. Another explanation may exist, however. 
Blood pressure variability increases with higher blood pressure. Further, the 
British Hypertension Society protocol 1993 uses sequential measurements. This 
may be the reason that, owing to the increased blood pressure variability, the 
accuracy of most devices tends to decrease at higher blood pressure levels. 
Consequently, the accuracy of blood pressure measuring devices may be 
underestimated at higher blood pressure levels. 
Conclusion  Currently used automated blood pressure measurement devices 
seem to be less accurate at increasing blood pressure levels. It is important 
to be aware of this phenomenon when treating hypertensive patients. 
The reported decrease in accuracy, however, may well be explained by the 
increasing blood pressure variability at increasing blood pressure and the use 
of sequential measurements. If this is the case, then the accuracy of these 
devices is perhaps underestimated.
Accuracy at increasing blood pressure levels
65
Introduction
Hypertension is one of the major risk factors for the development of cardiovascular 
disease. Therefore, accurate detection of patients with hypertension is very 
important. Increasingly, blood pressure (BP) measurements are done with 
devices measuring BP oscillometrically. It is frequently stated in validation 
studies that automated devices become less accurate at increasing BP levels.1 
This has been shown to be correct for six ambulatory devices validated in the 
past.2 Whether the same is still true for more recently validated ambulatory 
and non-ambulatory systems remains to be seen. We therefore analysed data 
obtained from validation studies performed between 1993 and 2003 regarding 
the accuracy of BP measuring devices at different BP levels. These devices 
were tested according to the British Hypertension Society (BHS) protocols or 
the protocol of the Association for the Advancement of Medical Instrumentation 
(AAMI).3,4
Methods
Using Pubmed (www.ncbi.nih.gov/entrez/query.fcgi) validation studies were 
selected on the basis of the following criteria: 1) studies had to have been 
performed between 1993 and 2003. 2) Validation was performed according to 
the BHS protocols or AAMI criteria. Use of a slightly modified BHS protocol 
(instead of the original) with, for example, two instead of three observers, 
was accepted. 3) Studies had to report the accuracy of the devices according 
to different BP levels. If not available, the authors were asked to give this 
information. 4) Devices had to measure BP auscultatorily (e.g. auscultatory 
mode for ambulatory BP measuring devices) or oscillometrically. 5) Studies that 
tested the accuracy of the BP measuring device during exercise, in pregnant 
women or in children were excluded. Devices listed in a recent review article 
were used as a directive for selection.5 Studies were divided according to the 
BP measurement system tested: ambulatory or non-ambulatory.
Results
On the basis of the criteria mentioned, 12 studies reporting on ambulatory BP 
measuring devices and 18 studies reporting on the accuracy of non-ambulatory 
devices could be selected.1,2,6–15,16–34 Of these, the studies reporting on the 
accuracy of 13 different ambulatory and nine different non-ambulatory devices 
were useful (Tables 1 and 2). We approached a number of authors for additional 
data. Unfortunately, there was only minimal response on the requests for 
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information. Only Altunkan et al.13 could provide us with additional data. The 
minimal response was probably owing to the lack of time for most authors or 
because of the longer time period that had evolved since their original study. 
As shown in Tables 1 and 2, only a limited number of studies reported the mean 
difference and standard deviation of differences for the different BP levels. 
Therefore, the percentages of differences ≤ 5 mmHg across the different BP 
levels were used as a measure of accuracy: the percentages are plotted for the 
different devices in Figure 1 and 2. As with other biological parameters, one 
can expect the difference between actual and measured BP (i.e. the absolute 
BP difference) to increase with BP level. 
Table 1. Accuracy of nine blood pressure measuring devices according to blood pressure level: 
non-ambulatory oscilometric devices for self-measurement or clinical use
Device  BP level         BHS grade   Percentage                   AAMI
       difference               (mean±SDD)
       ≤ 5 mmHg                  (mmHg)  
 DBP SBP DBP SBP DBP SBP DBP SBP
Omron HEM-705 CP1 <80 <130 A C 69 49 1±7 -2±6  
 80-100 130-160 A A 88 60 -1±4 -2±6
 >100 >160 B C 64 47 -2±7 -3±8
Welch-Allyn VSM27 <80 <130 A A 81 82 n.g. n.g.
 80-100 130-160 B A 56 73 n.g. n.g. 
 >100 >160 A A 78 70 n.g. n.g.
A&D UA-76726 <80 <130 B A 78 88 0±5 1±4 
 80-100 130-160 A B 81 74 0±5 -1±5
 >100 >160 B C 82 70 -1±6 -3±8
Microlife BP 3BTO-A24 <80 <130 A A 77 80 n.g. n.g.
 80-100 130-160 A A 70 61 n.g. n.g.
 >100 >160 B C 56 50 n.g. n.g.
Omron-MIT25 <80 <130 A A 69 70 n.g. n.g.
 80-100 130-160 A B 73 54 n.g. n.g.
 >100 >160 B B 67 58 n.g. n.g.
Welch-Allyn VSM34 <80 <130 B C 52 46 -2±7 -6±6
 80-100 130-160 C D 45 28 -7±6 -8±6
 >100 >160 D C 31 31 -7±7 -11±14
Philips HP 53321 <80 <130 A C 69 51 -2±5 -5±5  
 80-100 130-160 A B 72 50 -4±5 -4±6
 >100 >160 A D 67 32 -4±5 -9±9 
Nissei DS-1751 <80 <130 B B 73 59 0±9 -4±6
 80-100 130-160 A D 69 24 -4±7 -9±6
 >100 >160 A D 67 24 -4±6 -12±11
Dinamap 8100a) 23 <80 <130 D B 42 65 n.g. n.g.
 80-100 130-160 D B 52 70 n.g. n.g.
 >100 >160 D C 39 62 n.g. n.g. 
BP, blood pressure; BHS, Britsh Hypertension Society; SDD, standard deviation of differences; DBP,
diastolic blood pressure; SBP, systolic blood pressure; n.g., not given. a)Tested according to the BHS 
protocol of 1990.
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The relative difference, however, will be less dependent on the actual BP 
level. Perhaps using percentages instead of absolute values is preferable. 
We therefore calculated both the relative and absolute differences for the 
different BP levels using data from two devices we recently tested: the Welch 
Allyn Vital Signs Monitor, an oscillometric upper arm device and the Omron RX-M, 
an oscillometric device measuring BP at the wrist 34,35 
 
Figure 1.  Number (percentages) of differences ≤ 5 mmHg for non-ambulatory blood pressure 
measuring devices for different diastolic and systolic blood pressure levels. The device that was 
tested according to the BHS protocol of 1990 is shown using a broken line. The thresholds shown on 
the right of the figure concern the BHS protocol of 1993. BHS, British Hypertension Society.
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Results are shown in Figures 3 and 4, for diastolic and systolic BP. As can be seen 
for the Welch Allyn Vital Signs Monitor, the absolute difference increases, while 
the relative difference remains the same for increasing BP levels. The same 
results are found for the Omron RX-M, although for diastolic BP the absolute 
difference appears to be more constant for different BP levels.
Figure 2. Idem as in Figure 1, for ambulatory blood pressure measuring devices. Open symbols 
designate auscultatory and closed symbols designate oscillometric blood pressure measuring devices. 
Devices that were tested according to the BHS protocol of 1990 are shown using broken lines. The 
thresholds shown on the right of the figure concern the BHS protocol of 1993. 
BHS, British Hypertension Society.
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Table 2.  Accuracy of 14 blood pressure measuring devices according to blood pressure level: 
ambulatory blood pressure monitoring devices
Device  BP level         BHS grade   Percentage              (mean±SDD)                  
       difference                  
       ≤ 5 mmHg                     
 DBP SBP DBP SBP DBP SBP DBP SBP
Tensioday8 <80 <130 A A 81 86 0±5 1±4  
 80-100 130-160 A A 78 67 2±6 2±7
 >100 >160 A A 87 85 1±4 1±6
Meditech ABPM-047 <80 <130 B B 54 54 n.g. n.g.
 80-100 130-160 B B 52 51 n.g. n.g. 
 >100 >160 B B 54 51 n.g. n.g.
SpaceLabs 902176 <80 <130 A A 67 73 n.g. n.g. 
 80-100 130-160 A A 71 72 n.g. n.g.
 >100 >160 B A 67 69 n.g. n.g.
SpaceLabs 902072 <80 <130 B B 79 77 n.g. n.g. 
 80-100 130-160 B B 68 70 n.g. n.g.
 >100 >160 B B 52 58 n.g. n.g.
Nissei DS-250a)13 <80 <130 n.g. n.g. n.g. n.g. -3±4 0±7
 80-100 130-160 n.g. n.g. n.g. n.g. -1±7 -5±10
 >100 >160 n.g. n.g. n.g. n.g. -1±9 -1±9
Mobil O Graph12 <80 <130 A A 68 61 n.g. n.g.
(version 12) 80-100 130-160 A A 71 71 n.g. n.g.
 >100 >160 A C 74 43 n.g. n.g.
Schiller BR-102 (Au)10 <80 <130 A C 60 47 -3±4 -5±5
 80-100 130-160 B B 70 62 -3±3 -2±4
 >100 >160 C A 47 66 -4±6 -2±4
Schiller BR-102(Oscill)12 <80 <130 A C 61 48 -3±4 -3±5  
 80-100 130-160 B C 54 46 -4±4 -5±7
 >100 >160 C D 43 29 -5±6 -9±8 
CH-Druck (Au)2 <80 <130 A A 84 90 n.g. n.g.
 80-100 130-160 A B 88 75 n.g. n.g.
 >100 >160 C B 75 81 n.g. n.g.
Profilomat (Au)2 <80 <130 A A 83 82 n.g. n.g.
 80-100 130-160 A B 82 74 n.g. n.g.
 >100 >160 D C 74 77 n.g. n.g.
Novacor DIASYS 200R (Au)2 <80 <130 C C 68 71 n.g. n.g.
 80-100 130-160 C C 60 64 n.g. n.g.
 >100 >160 B C 73 55 n.g. n.g.
Pressurometer IV (Au)2 <80 <130 D B 60 74 n.g. n.g.
 80-100 130-160 D C 63 62 n.g. n.g.
 >100 >160 D D 39 53 n.g. n.g.
Takeda TM-2420 (Au)2 <80 <130 D B 56 71 n.g. n.g.
 80-100 130-160 D C 65 64 n.g. n.g.
 >100 >160 D D 67 42 n.g. n.g.
Profilomat II11 <80 <130 B B 57 56 -1±7 -1±6
 80-100 130-160 B D 53    39      1±7 2±9
 >100 >160 C D 47 31 2±9 4±11
BP, blood pressure; BHS, British Hypertension Society; SDD, standard deviation of differences; DBP, 
diastolic blood pressure; SBP, systolic blood pressure; ABPM, ambulatory blood pressure monitoring; 
n.g., not given; Au, auscultatory; Oscill, oscillometrically.
a)Validated according to the International Protocol. Additional data were provided by Altunkan et al.13 
Results for this device are not shown in Figure 2 because relevant data were missing. Devices from 
Ref.2 were tested according to the BHS protocol of 1990.
70
Chapter 2.5
Figure 3. Absolute and relative differences between measurements by the Welch 
Allyn Vital Signs Monitor and standard mercury sphygmomanometer for diastolic 
(upper panel) and systolic (lower panel) blood pressure
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Figure 4. Idem as in Figure 3, for the Omron RX-M
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Discussion
On the basis of the results of the studies available for this report, it could be 
concluded that the accuracy for most of the devices decreases at increasing 
BP levels. This would especially be the case for systolic BP in nonambulatory 
devices. We believe, however, that this conclusion would be incorrect. It 
is our opinion that BP measuring devices seem to become less accurate at 
increasing BP levels because of a combination of two factors: the sequential 
measurements used during validation studies and the increasing BP variability 
at increasing BP levels. 
BP has been shown to be more variable at increasing BP levels. Mancia et al.36 
showed that absolute short-term variability in BP was greater for hypertensive 
patients than for normotensive individuals. This was shown for systolic, diastolic, 
as well as mean arterial BP. For systolic BP, short-term variability increased from 
9.5 mmHg (for normotensive individuals) to 12.2 mmHg (for severe hypertensive 
patients). For diastolic BP, short-term BP variability increased from 6.1 mmHg 
(for normotensive individuals) to 9.0 mmHg (for severe hypertensive patients). 
The percentual BP variabilities, however, were similar. BP variability has been 
linked to target organ damage in hypertension and has been shown to be an 
independent predictor for cardiovascular mortality in a general population.37,38 
In the BHS protocol of 1993, sequential measurements are used for the validation 
of BP measuring devices. The absolute difference between test device and 
'the gold standard' (mercury sphygmomanometer) is calculated independent 
of BP level.3 The influence of the sequential measurements on the results of 
the validation of automated BP measuring devices was investigated by Atkins 
et al.39 They performed sequential BP measurements using the same mercury 
sphygmomanometer. The percentage of differences within 5 mmHg was only 
69% (for systolic BP), when comparing a BP measurement using the mercury 
sphygmomanometer with the mean of the measurement before and after the 
index measurement using the same device. The only explanation could be that 
BP fluctuated during the sequential measurements.
Owing to the increasing variability of BP at increasing BP levels, analysis using 
the absolute BP differences in sequential measurements will underestimate 
the accuracy of BP measuring devices at these levels. Noticeably, all devices 
in the first study showing decreasing accuracy at increasing BP levels were 
tested using sequential measurements.2 Analyses of the data both from the 
literature and from our own studies with the Welch Allyn Vital Signs Monitor 
and the Omron RX-M indeed shows that the absolute difference seems to be 
dependent on the BP level, whereas the relative difference seems to be more 
or less independent of the BP level.
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Another explanation for the current findings is that the oscillometric method 
itself may be responsible. The exact way in which the systolic and diastolic 
BPs are determined using oscillometry is held secret by the different device 
manufacturers. It may well be that the observed inaccuracy is due to the 
algorithm used to calculate the systolic and diastolic BP values.
Decreasing accuracy of BP measuring devices at increasing BP levels is a very 
troublesome phenomenon, as hypertension is the indication for their use. 
The consequence may be that patients with hypertension can erroneously be 
classified as non-hypertensive and treatment withheld. Furthermore, in treated 
hypertensive patients the necessary adaptation of treatment will not take 
place, while BP is judged adequately regulated. Alternatively, it is possible that 
a device gives readings that are too high. Non-hypertensive individuals could,
therefore, erroneously be classified as hypertensive.
Owing to the limited studies available for this report, selection bias could have 
been introduced. The studies used, however, are well performed and the results 
are consistent, especially with regard to systolic BP. It is within the BP range 
of 80–100 mmHg for diastolic BP and 130–160 mmHg for systolic BP that the 
threshold for the diagnosis of hypertension is encompassed. The effect of the 
BP level on the accuracy of BP measuring devices within this important BP range 
cannot be estimated on the basis of the information currently available.
Validation studies should continue to report the accuracy of devices at different 
BP levels, although not explicitly stated in the new 'International Protocol'.40 
Besides the frequently shown Bland–Altman plots, we would like to report 
separately the accuracy at the different BP levels as shown in Tables 1 and 
2. With the new 'International Protocol', however, the sample size of each BP 
category being 11 is quite small. 
In conclusion, we would like to state that BP measuring devices seem to become 
less accurate at increasing BP levels. Owing to sequential measurements used 
during validation and to the increasing variability of BP at increasing BP levels, 
the decreasing accuracy of BP measuring devices, however, may have been 
overestimated. 
Nonetheless, this is a very troublesome phenomenon as accuracy at increasing 
BP levels is most important for diagnosis and follow-up of hypertensive 
patients. Perhaps the accuracy of a device at different BP levels could become 
an independent criterion for recommending in favour of or against its use in 
clinical practice. It is our opinion that validation reports should not only address 
the absolute but also the relative accuracy at different BP levels.
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Abstract
The market for automated blood pressure measuring devices is growing rapidly. 
Many patients want to buy a device for blood pressure measurement at home 
and ask their physician for advice about which one to choose. In this article 
an overview is given of the different devices available for blood pressure 
measurement and possible pitfalls in the interpretation of measurements taken 
at home are pointed out. A second article will specifically address those devices 
that are used to take blood pressure measurements at the wrist.
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Introduction
The market for automated blood pressure measuring devices is growing rapidly. 
Home blood pressure measurement (HBPM) is becoming more and more popular. 
Many of the devices designed for HBPM have now been validated according 
to different protocols. Most (78%) of the 11 million devices for HBPM sold in 
2000 were produced by Japanese manufacturers.1 Of the sold devices, 64% are 
upper-arm devices and 35% are wrist devices.1 HBPM has been shown to have 
a stronger predictive power for mortality than screening blood pressure (BP).2 
Many patients with hypertension ask their general practitioners and specialists 
which device they should buy. The purpose of this article is to help physicians to 
better advise patients in choosing between different devices for HBPM. Moreover, 
it will help the physician to interpret the readings taken at home better and to 
pin-point possible pitfalls such as (reverse) white-coat hypertension or white-
coat effect.These and many other factors should be taken into account when 
medication changes are made based on home readings.
Overview of validation protocols currently in use
A number of validation protocols for BP measuring devices have been published 
in the past years. The most widely used are the British Hypertension Society 
(BHS) protocol 1990, which was revised in 1993, and the protocol of the 
Association for the Advancement of Medical Instrumentation (AAMI) published 
in 1987 and revised in 1992.3-6 Recently an effort has been made to develop a 
universal protocol in the form of an 'International Protocol'.7 In Germany the 
Deutsches Institut für Normierung (DIN) developed a protocol and in Australia 
another protocol has been drafted.8,9 Of these protocols, the BHS protocol 1993, 
the International Protocol and the AAMI 1992 protocol will be discussed briefly. 
In the BHS protocol 1993 a mercury sphygmomanometer is used as reference 
standard. In the main part of the protocol, BP measurements are done in 85 
subjects. In each subject seven BP measurements are performed alternately 
with the device being tested (read by one observer) and by two other observers 
with the mercury sphygmomanometer (Figure 1). After calculating the 
differences between the standard and the test device a grade for both systolic 
(SBP) and diastolic (DBP) blood pressure can be calculated using Table 1. Only 
devices with a grade A or B for both SBP and DBP are recommended for clinical 
use. In the International Protocol adjustments have been made to simplify the 
validation procedure of the BHS protocol 1993.
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Observer 1
Device (Observer 3)
Observer 2
BP 1
BP 1
BP 2
BP 3
BP 3
BP 4
BP 5
BP 5
BP 6
BP 7
BP 7
Figure 1. Sequential blood pressure measurements according to the British Hypertension Society 
protocol 1993 (also used in the International Protocol)
This was done by using the data from 19 validation studies performed according 
to the BHS protocol. A two-phased approach is used. During phase 1 sequential 
BP measurements are carried out in 15 subjects (according to the scheme shown 
in Figure 1). Requirements shown in Table 1 must be met in order to proceed 
to phase 2. This approach will help to eliminate very inaccurate devices in an 
early phase. When the device tested enters phase 2, measurements are done 
in an additional 18 subjects. Differences between test device and mercury 
sphygmomanometer have to be within the requirements shown in Table 1 in 
order to pass. So a pass/fail system has replaced the A,B,C and D grading system 
of the BHS protocol 1993. Analysis is done separately for systolic and diastolic 
BP. Only a few devices have been tested according to this new protocol so far. 
In the AAMI protocol mean differences and standard deviation of differences 
(SDD) are calculated. BP measurements are done in 85 subjects with three 
sets of comparative BP measurements for each subject. Measurements are 
taken by two trained observers. Simultaneous measurements are preferred, 
but sequential measurements are also allowed. To pass the AAMI protocol the 
absolute mean difference has to be ≤ 5 mmHg and SDD ≤ 8 mmHg (Table 1) for 
both systolic and diastolic BP. Comparisons with intra-arterial measurements are 
also allowed: ten measurements should be done simultaneously in a minimum 
of 15 subjects. The upper limits of acceptance (mean and SDD) are the same as 
for noninvasive measurements.6
Instructions for home measurement and factors influencing blood 
pressure
To obtain reliable results patients and/or their relatives should be instructed 
on how to perform home measurements. Many factors influence the BP that is 
measured at a given moment and in a given situation.10,11 There are factors that 
influence the actual BP level and factors that are related to the method of BP 
measurement itself.
These are shown in Figure 2. Patients should be aware of a number of these 
factors when measuring BPs at home. Each measurement should be done only 
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                                Absolute difference between standard and 
 test device (mmHg)*
Grade             ≤ 5 mmHg ≤ 10 mmHg ≤ 15 mmHg
Cumulative percentages
A 60 85 95
B 50 75 90
C 40 65 85
D                      Worse than C  
*To achieve a certain grade, all percentages must be ≥ those in the table, n=255
Table 1. Grading criteria for sequential measurements according to the British Hypertension 
Society (BHS), the International Protocol and the Association for the Advancement of Medical 
Instrumentation (AAMI). All calculations should be done separately for systolic and diastolic blood 
pressure4,6,7
BHS Protocol (1993)
   
Phase 1: Measurements1 <5 mmHg <10 mmHg <15 mmHg
At least one of 25 35 40
Phase 2.1: Measurements2 <5 mmHg <10 mmHg <15 mmHg
All of  60 75 90
Two of 65 80 95
Phase 2.2: Measurements3 2/3 <5 mmHg 0/3 within 5 mmHg
Two of  22
All of  3
1 After measurements in 15 subjects (45 comparisons) at least 25 comparisons should lie within 5 
mmHg or at least 35 within 10 mmHg or at least 40 within 15 mmHg to proceed to phase 2. 2 After 
measurements in all 33 subjects 60, 75 and 90 comparisons should lie within 5, 10 and 15 mmHg, 
respectively. Also, 65 comparisons should lie within 5 mmHg and 80 within 10 mmHg or 65 within 5 
mmHg and 95 within 10 mmHg or 80 within 10 mmHg and 95 within 15 mmHg. 3 To complete phase 
2.2 in 22 of the 33 subjects at least two out of three comparisons should lie within 5 mmHg and at 
most 3 of the 33 subjects can have all three comparisons over 5 mmHg apart.
International Protocol (2002)
   
                  
Mean difference Absolute value ≤ 5 mmHg and standard deviation of  
differences ≤ 8 mmHg
4 In 85 subjects, 3 readings/subject, n=255
 
AAMI4
after proper preparation, i.e. patients should begin measurements only after 
at least five minutes of rest.12 Measurements should preferably be done while 
sitting in a comfortable chair. Care should be taken to position the centre of 
the cuff at heart level. The cuff size should be appropriate for the size of the 
arm and placed with the centre over the brachial artery. During measurements 
there should be no talking. A device properly validated and found accurate 
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Dietary factors
Body weight
Salt (sodium chloride)
Potassium
Calcium
Caffeine
Body position
Sitting
Supine
Standing
Patient preparation
Rest in chair for 5 minutes
before first measurment
Centre cuff at heart level
No talking
Room temperature
No measurement after
heavy exercise, recent 
meal or with full bladder
Timing of blood pressure
measurement
Day-night pattern
Time since medication intake
Season
Measurement done by
Patient self
Relative of patient
Nurse
Physician
Actual blood pressure
Site of blood pressure measurement
Upper arm
Wrist
Finger
Measurement at left or right arm
Examiner-related
Impaired hearing or sight
Expectation bias
Terminal digit perference
Parallax error
Reporting errors
Cuff size and arm position
Measured blood pressure
Device used for measurement
Mercury sphygmomanometer
Oscillometric device
Aneroid device
Figure 2. Factors influencing the actual blood pressure level and factors accounting for the 
difference between actual blood pressure and measured blood pressure level
enough for home measurement should be used. It could be argued that BP 
measurements should only be done by those who are equipped to do so, i.e. 
healthcare professionals. However one should keep in mind the following 
citation: 'Indirect BP measurement is one of the most frequently performed 
healthcare procedures. Because BP measurement is a simple procedure, it is 
taken for granted that all graduates from medical training programmes have 
the ability to record accurate, precise and reliable BP readings. However, 
research since the 1960s has shown this assumption to be false. Most health 
professionals do not measure BP in a manner known to be accurate and 
reliable. If you doubt this statement, watch as BPs are taken in your own 
clinical setting to determine whether the guidelines are followed, and then 
examine recorded readings for signs of observer bias.'10 So, adequate training 
and education in BP measurement are pivotal and more important than the 
person who performs the measurements. Self-measurement of BP is feasible for 
the majority of hypertensive patients.13 Proper instruction with, for example, a 
short teaching session at the outpatient clinic should preferably be given to all 
patients performing home measurements. 
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After thorough instruction, mercury and aneroid sphygmomanometers could 
also be used for self-measurement. However aneroid devices have been shown 
to become inaccurate over time.14 Patients should be instructed to report 
all measurements. No values should be discarded. Memory-equipped devices 
could help to check the values reported by patients.15 To obtain reliable 
results a sufficient number of measurements should be done. Three successive 
measurements two times a day (before meals, between 06.00 and 08.00 and 
between 18.00 and 20.00) for at least three to four days are recommended.16
BP measured at home will not automatically give the same results as BP 
measured at the office. About 10 to 15% of hypertensive patients will have 
isolated office hypertension (widely known as 'white-coat hypertension'), in 
which persistent office hypertension is accompanied by home BP values below 
130/85 mmHg.17 Indeed many factors influence the BP measured in the two 
situations. As with ambulatory blood pressure measurement (ABPM), one would 
expect to measure lower BPs at home as compared with in the office. However 
the opposite is also commonly seen.18 Wing et al. showed that in a group of 
713 older hypertensives, 21 to 41% of patients had higher daytime systolic or 
diastolic ambulatory BPs than office readings. This was confirmed by research 
at our own institution (Aksoy, unpublished data). BP measurement is not easy 
and the interpretation of the values measured is not at all easy, indeed it is 
rather complex. The development of automated BP measuring devices for use 
in the office and at home has actually made interpretation even more difficult, 
because different devices are commonly used in these different settings. To 
help interpret the BP values obtained during self-measurement, thresholds 
for normality of self-measured BP have been proposed as shown in Table 2.19 
These values are mainly based on cross-sectional studies and not yet related to 
cardiovascular prognosis.
Table 2.  Proposed thresholds for automated measurements of blood pressure19
 Blood Pressure (mmHg) 95th Percentiles1 Normotension2 Hypertension3
Ambulatory 24 hour 132/82 ≤130/80 >135/85
 Daytime 138/87 ≤135/85 >140/90
 Night-time 123/74 ≤120/70 >125/75
Self-recorded Morning 136/85 ≤135/85 >140/90
 Evening 139/86 ≤135/85 >140/90
 Morning and evening 137/85 ≤135/85 >140/90
1 Mean values for the 95th percentiles for normotensive subjects in large-scale studies. 
2 Obtained by rounding off downwards to the next blood pressure ending in 0 or 5 mmHg. 
3 Obtained by rounding off upwards to the next blood pressure ending in 0 or 5 mmHg.
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(Dis)advantages of home measurement
Different devices can be used for HBPM: the mercury sphygmomanometer, 
aneroid devices and oscillometrically measuring devices. The last category of 
devices has won the 'contest' for HBPM, because of their ability to perform 
measurements automatically. HBPM has several advantages. It can provide 
us with more measurements than office readings. It can help to diagnose 
isolated office hypertension, to quantify the 'white-coat effect' and it may 
help to improve compliance to therapy, improving BP control. Terminal digit 
preference and expectation bias is no longer a problem. Measurements are 
independent of the hearing of the observer. The costs of self-measurement 
are lower than for ABPM.20 However, in contrast to ABPM, no BP values can be 
obtained at night and the prognostic value of self-measurement needs further 
investigation.21 The device used for self-measurement has to be validated and 
accurate. Thresholds for normal levels are still under investigation. Mengden 
et al. showed that there was a substantial error in the reporting of the BP 
values obtained during self-measurement by hypertensive patients during two 
weeks.15 Some patients omitted high BP readings. This bias may be reduced 
by using memory-equipped BP devices.15 Another disadvantage is that it is not 
possible to control the circumstances in which measurements are taken. Also 
there is no information about proper cuff position during measurements. 
Automated devices validated for home use
A substantial number of devices for self-measurement have been validated 
according to the British Hypertension Society protocol, the International 
Protocol or the protocol of the Association for the Advancement of Medical 
Instrumentation. Most of these devices measure BP oscillometrically. The 
development of the oscillometric technique goes back to the late 19th century. It 
is based on the assumption that the maximal oscillation in the cuff air pressure 
observed during deflation corresponds to the mean arterial pressure. Systolic 
and diastolic BP values are then computed through a specific algorithm.22 These 
algorithms are kept secret, differ per device and can be changed easily.
Table 3 shows the devices that have been validated for self-measurement at 
the upper arm.22 A device can be either recommended (i.e. fulfilling the AAMI 
criteria for both systolic and diastolic BPs and achieving a BHS grade B or A for 
both systolic and diastolic blood pressures) or not recommended (i.e. failing 
the AAMI criteria and achieving a BHS grade C or D for either systolic or diastolic 
pressure). A device achieves a 'questionable recommendation' when there is 
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uncertainty about the strength of evidence (e.g. protocol violation, results 
presented only in abstract form etc).23
Table 3.  Automated blood pressure measuring devices for self-measurement at the upper arm that 
have been validated using the protocols of the British Hypertension Society (BHS), the International 
Protocol or the protocol of the Association for the Advancement of Medical Instrumentation (AAMI) 
– devices measure blood pressure oscillometrically unless otherwise stated (adapted with permission)23
  Protocol
Device AAMI  BHS1 Year Recommendation
Omron HEM-400C Failed  Failed2 1990 Not recommended
Philips HP5308 (Au)3 Failed  Failed2 1990 Not recommended
Philips HP5306/B Failed  Failed2 1990 Not recommended
Healthcheck CX-5 060020 Failed  Failed2 1990 Not recommended
Nissei analogue monitor (Au)3 Failed  Failed2 1990 Not recommended
Systema Dr MI-150 Failed  Failed2 1990 Not recommended
Fortec Dr MI-100 Failed  Failed2 1990 Not recommended
Philips HP5332 Failed  C/A 1996 Not recommended
Nissei DS-175 Failed  D/A 1996 Not recommended
Omron HEM-705CP Passed   B/A 1996 Recommended
Omron HEM-706 Passed  B/C 1994 Not recommended
Omron HEM-403C Failed  C/C 1995 Not recommended
Omron HEM-703CP Passed  NA4  1994 Questionable
Omron M4 Passed  A/A 1998 Questionable
Omron MX2 Passed  A/A 1998 Questionable 
Omron HEM-722C Passed  A/A 1997 Questionable
Omron HEM-722C Passed  A/A 1999 Recommended
Omron HEM-735C Passed  B/A 1999 Recommended
Omron HEM-713C Passed  B/B 1996 Recommended
Omron HEM-737 Intellisense Passed  B/B 1998 Recommended
Visomat OZ2 Passed  C/B 1998 Not recommended
1 According to the BHS protocol separate judgements are given to systolic and diastolic blood 
pressures, e.g. A/A both very good, C/A insufficient for systolic, but good for diastolic blood 
pressure. 2 In the first seven devices grading criteria had not yet been established. 3Au= auscultatory. 
4NA = not applied.
Most devices become more inaccurate at higher BP levels. This has been shown 
for ambulatory blood pressure measuring devices, but in general applies for 
most automated BP measuring devices.24 This is in part attributable to the 
design of the BHS protocol: independent of the BP level the absolute difference 
is used to calculate the grades.
Chapter 3.1
88
Conclusion
As can be seen in Table 3, many devices have been tested so far. However, 
only a few have achieved at least a grade B for both systolic and diastolic BP 
according to the BHS protocol or have passed the International Protocol. Based 
on the results shown in this Table one of the Omron devices graded B/B or better 
could be advised for HBPM. The field of BP measurement is developing rapidly. 
Recently the Omron-MIT has been validated: this device measures oscillations 
during inflation instead of deflation.25 Wrist devices are also becoming more 
and more popular and will be addressed in a separate article. 
O’ Brien et al. periodically publish an update on validated devices in the British 
Medical Journal.23 Devices that have passed the BHS protocol can also be found 
on the website of the British Hypertension Society: http://www.hyp.ac.uk 
(blood pressure monitors).
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Abstract
Devices measuring blood pressure oscillometrically at the wrist are becoming 
more and more popular. These devices are small, easy to handle and can 
measure blood pressure without the need to undress. However, few of the 
wrist devices have been validated properly, i.e. according to internationally 
accepted protocols. In this article current literature on wrist blood pressure 
measuring devices is presented. The importance of positioning the wrist at 
heart level for accurate measurements is stressed.
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Introduction
The first devices constructed to measure blood pressure in humans were devices 
measuring blood pressure at the wrist.1 Early experiments in this field in the 19th 
century eventually led to the development of the conventional blood pressure 
measuring technique at the upper-arm by Scipione Riva Rocci.2 However, the art 
of feeling the pulse has an even longer history, going back to Chinese medicine. 
Nowadays, oscillometric blood pressure (BP) measuring devices for home 
blood pressure measurement (HBPM) are becoming increasingly popular. When 
asked, patients choose HBPM as the preferred method for measuring BP over 
ambulatory blood pressure measurement (ABPM) or measurements by the nurse 
or physician.3 Moreover HBPM has been shown to have a stronger predictive 
power for mortality than screening BP measurement.4 Over 11 million devices 
for HBPM were sold world-wide in 2000.5 Most of these devices measure blood 
pressure at the upper-arm. However the proportion of the sold devices that 
measure BP at the wrist is increasing.5 Devices measuring BP at the finger have 
shown to be inaccurate.6 Many patients ask their physician for advise on which 
device to buy. Using the available literature on wrist BP measuring devices this 
overview will hopefully help physicians to advise their patients better in their 
choice for a particular BP measuring wrist device. 
Factors determining blood pressure level at the wrist
Many factors determine the BP measured at a given moment. In general there 
should be an adequate resting period before starting the measurements. 
Differences in the order of 5 to 10 mmHg can result from differences in arm 
position.7 The influence of arm position on the measured blood pressure level 
is due to the influence of the hydrostatic pressure: raising the arm (or wrist) 1 
cm lowers the blood pressure by 0.7 mmHg and vice versa.8 The cuff should be 
held at heart level, i.e. at the level of the right atrium. This generally means 
midway between the jugular notch and the xiphoid process.7 Because of its 
more distal position accurate positioning of the cuff at heart level is of even 
more importance for BP measurement at the wrist. The importance of the 
arm position on measured BP level has led to the development of a positioning 
system by Braun®.9 A wrist BP device equipped with an inclination sensor helps 
to manoeuvre the patient’s wrist to the same position for every measurement. 
This ensures that subsequent measurements are comparable.
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The measured BP level is further influenced by flexion and extension of the 
wrist.10 BP measured with the wrist in palmar flexion is significantly higher 
than that measured in palmar extension. BP measured in palmar dorsiflexion is 
significantly lower than that in palmar extension (for both diastolic and systolic 
BP). Besides these positional aspects, the BP itself is different at the wrist 
compared with the arm. Moving more distally from the ascending aorta to the 
radial artery, systolic BP increases and diastolic BP decreases, hence pulse 
pressure increases.11 Most wrist BP measuring devices are validated relative 
to upper arm BP measurements. So differences in BP between these two 
measurement sites can be expected from the outset. However, mean arterial 
pressure differs only slightly.12
Instruction for self-measurement and (dis)advantages of wrist devices
Proper instruction is pivotal to be able to obtain reliable results. Patients 
should be instructed on how to operate the device and to adequately register 
all measurements taken. A short course should preferably be given at the 
outpatient clinic. Unless the device has been equipped with a positioning system, 
proper positioning of the cuff at heart level should be stressed. HBPM can have 
several advantages. These are shown in Table 1. HBPM can help to establish the 
diagnosis of hypertension, to find cases of white-coat hypertension, assess the 
efficacy of antihypertensive therapy, evaluate the effect of dose adjustments,
detect unexpected BP derangements, reduce costs and to increase 
compliance.1,13 However BP levels during sleep are not obtained as they are in 
ABPM, reference values have not been firmly established and misreporting of the 
measured BPs can occur. The cut-off values for hypertension are lower for the 
BP measured at home than at the office.4,14-16 This should be taken into account 
when interpreting BP measurement taken at home. BPs measured at home can 
be lower than at the office as part of white-coat hypertension. However the 
opposite (BP at home higher than at the office) can also occur. This phenomenon 
has been described as the so-called reverse white-coat hypertension or masked 
hypertension, which is actually a misnomer and self-measurement related 
hypertension would be a better term.17 These phenomena make interpretation 
of BP levels acquired through self-measurements more difficult. Using wrist 
devices can have additional advantages: measurements at the wrist can be 
more comfortable, because these small, light-weight devices are easy to use, 
patients do not need to undress for measurements and measurements can be 
done in various circumstances.1 However, most wrist devices have not been 
properly validated or have been found inaccurate.
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Table 1. (Dis)advantages of home blood pressure measurement with automated devices in general 
and wrist devices in specific
general advantages
May help to diagnose hypertension
May help to detect white-coat hypertension/white-coat effect 
Stronger preditive power for mortality than screening blood pressure
Patient’s compliance may increase
Efficacy of antihypertensive medication and effect of dose adjustments can be better 
monitored
Earlier detection of derangement of blood pressure
advantages of wrist devices
Devices are light-weight
Easy applicability, greater comfort, no need to undress
Costs in general lower than ABPM/upper-arm devices
general disadvantages
No blood pressure measurements during the night
Reference values for hypertension not firmly established
Misreporting of measured blood pressure values possible
validation reports on wrist devices
Most devices not properly validated or not meeting BHS/AAMI criteria
Blood pressure level at the wrist is influenced by many factors 
(angle between hand and fore-arm, hydrostatic pressure)
Validation reports on wrist devices
Validation studies on wrist blood pressure measuring devices are scarce. The 
British Hypertension Society (BHS) protocol 1993 and the protocol of the 
Association for the Advancement of Medical Instrumentation (AAMI) are the 
most widely used protocols for validating BP measuring devices.18,19 For a short 
review of these protocols we would like to refer to our article on upper-arm 
devices. In a recent review by O’Brien only three wrist devices were shown 
to be tested by the British Hypertension Society (BHS) and/or Association for 
the Advancement of Medical Instrumentation (AAMI) criteria.20 Only one device 
passed the requirements of these protocols. For this review, we selected 
well-performed studies using the following criteria: a minimum number of 40 
patients had to be included and an internationally accepted protocol (BHS or 
AAMI) had to be used as a guideline to evaluate the test device. The studies 
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that fulfilled these criteria are presented in Table 2. Table 3 shows the rest of 
available validation reports on wrist BP measuring devices. 
Comparison between different validation reports testing the same device is 
quite difficult because validation is not always carried out in the same way. 
Moreover it is often difficult to determine which type of device has actually 
been tested, because the type and serial number of the device is not always 
stated exactly. In general, in comparison with oscillometric measuring devices 
at the arm, wrist devices seem to be less accurate.
Table 2.  Validation reports on wrist devices, including at least 40 patients and using BHS- or AAMI- 
protocols as a guideline10,21-28
Device  N   Standard         Mean difference (±SD) AAMI BHS
                       (device-standard) 
    SBP DBP
BP 200021  86 M 0.1±7.1 1.9±7.0 P/P
Boso-Mediwatch22* Nt 20 M 3.9(0.1;7.6) 7.0(4.7;9.2) 
 Ht 20 M -5.8(-11.6;-0.3) -5.5(1.4;6.3) 
Klock23  255 M 16±25 6±17 F/F
Matsushita Denko EW10  92 M 2.3±10.2 5.6±8.6  D/B
NAiS EW 2824 S 125 An -1.1±5.0 -1.7±3.0 
 C 40 An -1.9±2.9 -1.2±2.8
Nissei WS-310  87 M -4.6±8.3 -2.8±4.8 F/P B/A
Omron HEM 60110  173 M 2.1±9.7 -1.2±7.3  C/B
Omron RX (HEM 608)26  85 M 0.3±9.0 2.6±9.0 F/F B/B
Omron RX25  87 M -4.9±8.8 -4.2±6.4 F/P B/A
Omron RX-M27  89 M 2.5±12.2 7.5±8.4 F/F D/D
Omron R328  85 M -5.7±6.2 -6.8±6.8 F/F D/D
Omron R322* Nt 20 M 3.2(0.6;5.8) 4.2(1.6;6.7) 
 Ht 20 M -5.8(-8.8;-2.8) -5.5(-9.3;1.6)   
M = mercury sphygmomanometer, An = aneroid sphygmomanometer, Nt = normotensives,
Ht = hypertensives, S = surgery, C = community, SBP = systolic blood pressure, 
DBP = diastolic blood pressure, P = passed; F = failed. * 95% confidence interval instead of SD.  
Conclusion
The market for automated BP measuring devices is growing rapidly. Particularly 
the sales of wrist devices are increasing. They have the advantage of a small 
volume and easy applicability. However, the development of these devices 
should be watched with caution. First we should recommend our patients to 
use only devices that have been properly validated. At present too few wrist 
devices have been validated according the protocols of AAMI and/or BHS, so no 
particular device can be recommended. 
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Secondly the readings with these devices should be interpreted with caution 
and compared with measurements with an ABPM and BP measurements at the 
office. Interpretation is further hindered by the lack of firmly established cut-
off values for normotension and hypertension at the wrist.
Thirdly, to be able to compare different wrist devices more easily, accurate 
description of type and serial number of the device tested is needed. Accurate 
and reproducible positioning of the wrist at heart level is crucial for BP 
measurement. However, we think that with recent innovative developments as 
the position sensor by Braun and developments yet to come, wrist BP measuring 
devices will gain a prominent place in BP measurement and BP control. Instead 
of attributing to the diagnosis of hypertension, wrist devices could be of help 
in giving follow-up data. That is, provided that sequential measurements are 
done in the same manner, wrist devices could help to give information about 
(changes in) blood pressure level over time.
Device N            Mean difference (±SD)           Standard
  SBP DBP AAMI
Intra-arterial measurements as standard
NAiS Matsushita BP Watch29 27 1.5±10.2 4.1±7.3 F/P  
NAiS BP Watch30 100 4.3±14.1 6.0±8.9 F/F
Omron HEM-60131 25 -4.0±18.0 3.0±9.0 F/F
Omron R332 100 -1±13.0 1.0±9.0 F/F
Oscillometric arm device as standard
NAiS BP Watch30 100 3.4±13.3 3.8±9.5 F/F  Hestia OZ80
Omron HEM-60133 26 -0.04±10.0 2.8±8.0 F/P   Visomat Hestia OZ40
Omron RX-M27 89 4.1±12.7 6.3±7.1 F/F      Omron HEM 705 CP 
BOSO medistar34 21 2±7  3±6  P/P    BOSO medicus
Ambulatory blood pressure monitor as standard
BP 20009 43 -1.5±13.7 5.2±7.9(P+)   A&D TM-2430
  -0.5±15.0 6.0±8.9(P-)  
Omron HEM-60131 50 n.g. n.g.          SpaceLabs 90207
SBP = systolic blood pressure, DBP = diastolic blood pressure, P = passed, F = failed, 
n.g. = not given.
Table 3. Various validation reports of wrist devices, not fulfilling the criteria stated in table 29,27,29-34
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Abstract
Drug adherence should be an important issue in everyday clinical practice. In 
asymptomatic conditions like hypertension adherence can be expected to be 
low and to decrease over time. We present five hypertensive patients in whom 
drug adherence was shown to be an important reason for inadequate blood 
pressure control. Different causes and risk factors of non-adherence as well as 
methods to estimate the level of drug adherence are discussed. A number of 
practical advices to increase drug adherence are given. Increased awareness 
of decreased adherence is the first important step to improve blood pressure 
control. 
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Introduction
Many patients have to take a great number of drugs during the day for varying 
medical conditions and for prolonged time periods. An increasing number of 
(asymptomatic) 'patients' are treated with drugs because of the presence of 
risk factors like hypertension and hypercholesterolemia (primary prevention). 
In order for primary prevention to be successful adequate drug adherence is 
crucial, as was recently stated by the World Health Organization (WHO).1
Haynes et al. defined drug adherence (compliance) as: 'the extent to which a 
person’s behaviour (in terms of taking medications, following diets, or executing 
lifestyle changes) coincides with medical or health advice'.2 This definition is 
still valid today. The term 'compliance' was first changed to 'adherence' and 
later to 'concordance'1,3 in order to stress the importance of autonomy of the 
patient. The physician offers the patient several treatment options and together 
they choose a specific treatment plan.1,3 In this article the term 'adherence' will 
be used.
The mean level of drug adherence is about 50% in chronic conditions. In one out 
of three patients drug adherence is good, in one out of three it is moderate and 
in one out of three it is insufficient.4 For the lifelong  treatment of asymptomatic 
conditions or risk factors like hypertension, the success of treatment depends 
largely on the level of drug adherence.
The next cases show the influence of adherence on the treatment results 
reached, in which case one has to think about insufficient drug adherence and 
which advices can be given to improve adherence.
CASE 1.  A 62-year-old single man was admitted to the department of general 
internal medicine because of fever and general weakness. He was known 
with hypertension, an inferior wall myocardial infarction and cerebrovascular 
accident. On the age of 61 patient underwent a percutaneous coronary 
intervention. In the foregoing years the patient had participated in various 
cardiovascular clinical trials. At admission he indicated to take the following 
drugs: bisoprolol, amlodipine, isosorbide dinitrate, acetylsalicylic acid, 
levomepromazine, oxazepam, medication because of participation in a 
randomised clinical trial and amoxicillin for several days. The systolic blood 
pressure (BP) at admission was 170 mmHg and the diastolic BP was 110 mmHg. 
The patient brought with him all the drugs he said to be using in several bags 
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(Figure 1). The bags contained a large number of predominantly unopened 
medication boxes. He was asked why he made the effort to fill every prescription 
at his pharmacy and subsequently did not take the drugs. He answered that 
after every visit to his physician, he had the intention to take the drugs as 
prescribed ('at every visit the physican looked at him so faithfully'), however 
after reading the instruction leaflet he decided not to take them.
CASE 2.  A 43-year-old man was referred to our clinic by a cardiologist because 
of therapy resistant hypertension. Despite treatment with five antihypertensive 
drugs systolic BP was still too high with levels between 180 to 210 mmHg 
and with levels of diastolic BP between 100 to 120 mmHg. There were signs 
of organ damage (electrocardiographic as well as echocardiographic left 
ventricular hypertrophy and an increased urinary albumin excretion rate of 
82 µg/min, normal < 20). Because further investigations showed no signs of 
secondary hypertension, insufficient adherence to the antihypertensive drugs 
was suspected. All the more because resting pulse rate was over 80 beats/
min, while using the beta-adrenoceptor blocker atenolol 100 mg once daily. A 
therapeutic blood level of this drug could not be demonstrated (< 0.04 mg/l, 
therapeutic level: 0.2-0.6 mg/l).
He was admitted to our hospital for a short period. Drug intake was checked 
during the hospital stay. The BP was lowered to 150 mmHg systolic and 95 
mmHg diastolic, while using four different drugs: atenolol 50 mg twice daily, 
hydrochlorothiazide 50 mg twice daily, nifedipine retard 40 mg twice daily 
and enalapril 10 mg twice daily. After a leave for the weekend the BP level 
had increased again to 180/142 mmHg and pulse rate increased from 65 to 90 
beats/min. Again the drug level of atenolol was subtherapeutic (< 0.04 mg/l).
Patient was followed up for a prolonged time period at the outpatient clinic. 
Figure 1. Bag filled with partially unopened medication boxes of 
patient 1.
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BP remained high, despite treatment with a great number of antihypertensive 
drugs. Several times blood levels of atenolol were determined (Figure 2), most 
of them where subtherapeutic. On several occasions the issue of insufficient 
drug adherence was discussed without any success.
CASE 3. A 48-year-old woman, was referred by an internist from a general 
hospital because of therapy resistant hypertension. Systolic BP was 240 mmHg 
and diastolic BP 140 mmHg during treatment with three antihypertensive drugs. 
There was also severe overweight of 99,7 kgs with a height of 169 cms. No 
signs of secondary hypertension were present. The BP did not change despite 
increasing the number of antihypertensive drugs to six. The number of drugs 
was subsequently reduced, without any change in BP.
Figure 2. Variable intake of atenolol of patient 2, reflected by fluctuating levels of atenolol. The 
fluctuating blood pressures and pulse rates were probably due to the varying intake of atenolol: for 
example sometimes several days a week and sometimes only once a week. The therapeutic range of 
atenolol levels is indicated by horizontal lines. SBP, systolic blood pressure.






               





















               





























 
At
en
ol
ol
 le
ve
l (
m
g/
l)
Sy
st
ol
ic
 b
lo
od
 p
re
ss
ur
e 
(m
m
H
g)
 a
nd
pu
ls
e 
ra
te
 (
/m
in
)
Chapter 4.1
110
Patient was admitted to our hospital for further investigations. Drug intake was 
monitored during her hospital stay. During treatment with two antihypertensive 
drugs, a beta-adrenoceptor blocker and a diuretic, BP was lowered from 
205/135 mmHg to 120-140 mmHg systolic and 70-85 mmHg diastolic. BP could 
be regulated well afterwards for a prolonged time period with systolic BPs of 
120 to 130 mmHg and diastolic BPs of 85-90 mmHg.
CASE 4.  A 35-year-old man was referred to our hospital because of therapy 
resistant hypertension. During treatment with three antihypertensive drugs 
his systolic BP was 160 mmHg and his diastolic BP 112 mmHg. Secondary 
hypertension was suspected, but additional investigations did not reveal any 
abnormalities. During treatment with an angiotensin converting enzyme (ACE) 
– inhibitor and a diuretic BP was lowered to a level of 130/86 mmHg. Further 
treatment and follow-up were done by his general practitioner.
Five years later patient was again referred because of difficult to treat 
hypertension. During treatment with three antihypertensive drugs (atenolol 
had been added by the general practitioner) BP was 220/140 mmHg. Despite 
treatment with atenolol resting pulse rate was high (between 80 to 95 beats/
min). A subtherapeutic atenolol level was measured. Insufficient adherence 
was suspected. During later visits at the outpatient clinic BP was much lower: 
135/95 mmHg and pulse rate was 58 beats/min. He told mistakenly to have 
used paracetamol (acetaminophen) instead of atenolol.
CASE 5. A 53-year-old woman was seen because of high BPs despite treatment 
with several antihypertensive drugs. She was known with an appendectomy, 
cholecystectomy, an abdominal extirpation of the uterus and an arthrodesis 
of the left knee after several orthopaedic operations. At the outpatient clinic 
BP was 206/112 mmHg and pulse rate 80 beats per min. Physical examination 
showed no abnormalities, except obesity (body weight 92 kgs, height 161 
cms). There were no signs of secondary hypertension. Laboratory investigation 
showed a potassium level of 4.8 mmol/l despite treatment with chlorthalidone. 
Gradually the number of antihypertensive drugs was increased. Finally she used 
a beta-adrenoceptor blocker, a diuretic and a vasodilating drug. Because there 
was no decrease of the BP patient was admitted to our hospital.
During treatment with chlorthalidone 50 mg once daily systolic BP was lowered 
after several days to 120 – 130 mmHg and diastolic BP to 75 – 80 mmHg. 
With chlorthalidone alone BP was lower than during treatment with three 
antihypertensive at the office. Moreover a clear decrease in the potassium 
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level was observed and an accompanying decrease in body weight (Figure 3). 
Chlorthalidone was not detectable in the blood at admission, but it was after 
several days of treatment (0.21 mg/l).
Insufficient drug adherence was suspected. Several times the importance of 
adequate adherence was discussed with our patient, however this did not 
improve the situation. At the outpatient clinic again much higher BPs were 
measured.
Discussion
Adherence should always be an important issue, but particularly with more or 
less chronic conditions that are not accompanied by symptoms.5 In the United 
States two out of three patients with known hypertension are either untreated 
or undertreated.6 One of the most important reason for this is insufficient ad-
herence.6 
Adherence is not an all or nothing phenomenon. The level of adherence can 
vary. In general the level of adherence that is required for treatment to be 
effective, is unknown. Besides the type of condition this will depend on half-
life, dosage prescribed and the number of doses per day of the drug and further 
on possible interactions with other drugs.7 For the treatment of hypertension it 
Figure 3. Effect of treatment with thiazide diuretic chlorthalidone (patient 5); decrease of 
potassium concentration and body weight.
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is assumed that minimally 80% of drugs prescribed in adequate amounts should 
be taken, to achieve a stable BP control.2,5  For patients infected with human 
immunodeficiency virus (HIV) adherence with antiretroviral therapy should be 
at least 95%.5
It is often difficult to recognize insufficient adherence. It should be considered 
when BP is not lowered despite adequate antihypertensive therapy. One can 
ask the patient about its drug adherence. If the patient admits to be non-
adherent (like case 1), improvement of adherence is often possible, because 
the subject of inadequate adherence has become debatable. Several direct 
and indirect methods exist to estimate the level of adherence (Table 1).4,5,7  
Unfortunately, the majority of these methods are not useful, because they are 
either too unpractical, too labour-intensive or too costly. 
Table 1.  Methods to estimate and to improve the level of adherence to antihypertensive drug therapy 
(adapted from4,5,7)
Method/criterion Advantage Disadvantage
Questionnaires, self reports Simple, inexpensive Unreliable
Pill count Simple Unreliable
Patient interview Simple Unreliable
Impression of the physician Simple Unreliable
Check whether prescriptions have Objective Filling prescription does not
been filled at the pharmacy  guarantee drug intake;
  patient can visit more than
  one pharmacy
Degree of BP lowering Simple Besides adherence other
  factors determine the degree
  of BP lowering 
Measure physiological marker, side Simple Absence of reaction/side
effect (for example pulse rate while  effect does not guarantee
using beta-adrenoceptor blockers,   insufficient adherence
decrease in body weight and decrease 
in potassium concentration while using
diuretics)
Electronic monitoring Accurate, results easy  Relatively costly; opening of
 to interpret the pill box thus not
  guarantee drug intake
Measure drug, metabolite Objective Unpractical, labour
or marker in blood or urine  intensive, cumbersome, 
  expensive  
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Actually there is no good standard to measure the level of adherence objectively. 
Certain side-effects of drugs can sometimes be indicative of adherence, for 
example the occurrence of ankle oedema while using calcium antagonists. 
Ankle oedema occurs in 14.6% of women and 5.6% of men using amlodipine.11 
After starting thiazide diuretics one can expect the potassium level and body 
weight to decrease and urea and uric acid levels to increase. Of course the 
absence of side effects does not exclude insufficient adherence.
With electronic monitoring a pill box equipped with a built-in chip is used. The 
date and time of opening of each pill box can be registered. The level of adherence 
can be estimated quite reliably using this method. If a patient deliberately 
would like to circumvent this method, then he or she would conscientiously 
have to open the pill-box every day for months and subsequently not take the 
drug. Burnier et al. used electronic monitoring to improve adherence in a group 
of patients with therapy resistant hypertension.8 Patients were informed that 
during two months adherence would be measured using electronic monitoring. 
For more than 50% of patients insufficient adherence was shown to be the 
reason for inadequate BP control.
Another method is to measure the concentration of a drug or its metabolite 
or marker in blood or urine of the patient. Although this method is objective, 
the concentration of only a limited number of antihypertensive drugs can be 
measured. The validity of this method depends on pharmacokinetic properties 
of the drug measured, like the elimination half-life. In the treatment of 
hypertension optimal long-term adherence is essential. Determining the 
concentration of an antihypertensive drug or marker with a short half-life 
will be less informative. Moreover adherence tends to increase in the period 
of a planned appointment to the doctor’s office.9 This phenomenon is called 
“white-coat compliance”.10 During the days preceding the visit to the doctor 
adherence is likely to increase. Therefore concentrations in plasma or urine of 
markers or drugs, measured during office visits are possibly not representative 
of long-term drug adherence, particularly when elimination half-life is short. 
However a repetitively not measurable or subtherapeutic drug level (cases 2 
and 4) does indicate that adherence is insufficient. Sometimes instead of the 
concentration of a drug, the effect of an antihypertensive drug on a particular 
enzyme system can be measured. For example ACE-activity can be measured to 
determine the level of adherence when using ACE-inhibitors. This method can 
not be used for captopril, because in vitro it easily dissociates from ACE.
Several determinants are important for the occurrence of insufficient drug 
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adherence. The influence of gender, race and socio-economic state of the 
patient is not entirely clear.5 The presence of a depression seems to be an 
important risk factor.13 (Alleged) side effects or the fear of side effects are 
often mentioned as a reason for non-adherence (case 1).10  Side-effects differ 
from one drug to the other and from patient to patient. Adherence is higher with 
ACE-inhibitors and angiotensin-II receptor antagonists, compared to diuretics 
and beta-adrenoceptor blockers. The first two categories of antihypertensive 
drugs have less side-effects.14 The level of adherence is also influenced by the 
organization of the outpatient clinic. Long waiting times will have a negative 
influence on the level of adherence.2
Which measures can help to improve adherence to antihypertensive drug 
therapy? First of all the schedule of drug intake should be as simple as possible 
(Table 2). A more complex schedule will decrease drug adherence. The adherence 
decreases proportionally to the number of daily doses prescribed.5,15
A good patient–physician relationship will improve drug adherence. Clear 
communication between patient and physician is very important. 40-80% of the 
information provided by a healthcare professional is immediately forgotten. 
The majority of patients is not deliberately non-adherent. Sometimes simple 
mistakes are the reason for non-adherence (case 4). In minimally 30% of patients 
forgetfulness is mentioned as the reason for non-adherence.5,16 Also holidays, a 
disease or start of new drugs by another physician can initiate non-adherence. 
The patient should be given enough time to incorporate the proposed drug 
schedule into his daily life activities. Admission to a hospital can sometimes 
improve adherence for longer periods. During the hospital stay it can be shown 
that BP is lowered with the drugs already prescribed at the outpatient clinic 
this can help to improve adherence. One should be aware that BP can drop too 
much when the same drug schedule is followed as in the outpatient setting. 
However, sometimes hospital admission fails to improve adherence.
Patients indicating that they have difficulties to adhere are often accessible for 
improvement. Accurate and extensive information and a motivating attitude of 
the physician can help to improve adherence. Self BP measurements with vali-
dated devices17 and contact using e-mail about the results of self-measurements 
can help to increase adherence, without much extra effort. A dedicated nurse 
can also improve long term results.18,19 It is often helpful to discuss the occur-
rence of side-effects and possible fears for side-effects with patients.
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Conclusion
An open discussion with patients about their drug taking behaviour with 
adequate instruction about the importance of good adherence should be an 
important part of every patient-physician contact. This is especially important 
for those patients that are asymptomatic and use drugs for primary prevention. 
The level of adherence is difficult to estimate. There are only few methods to 
measure it objectively. Insufficient adherence should be suspected whenever 
the desired BP goal is not reached.
 
Table 2. Methods to improve the level of adherence to antihypertensive drug therapy
(adapted from 4,5,17-19)
- Simplifying the medication regimen
- Use of memory aids: patient diary, medication box, watch equipped with alarm
- Provide adequate information on hypertension
- Motivating attitude of physician; invest in good physician-patient relationship
- Use help of other health care providers (nurses, pharmacists)
- Discuss the occurrence of side-effects and possible fear for side-effects
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Abstract
Objective Several methods have been described to measure adherence 
to prescribed drug therapy. However, most of these have been shown to be 
inaccurate. Bromide is an anion that is readily absorbed in the gut and has an 
elimination half-life of about 12 days. In the present study, we investigated 
the pharmacokinetic properties of bromide with the objective to use it as a 
measure of drug adherence. 
Methods Three groups of each 8 healthy volunteers took 15, 24 or 30 mg 
potassium bromide, respectively, daily for 20 weeks. Serum concentrations 
of bromide were measured every two weeks. Results: There was a linear 
relationship between the daily dosage taken and the mean increase of bromide 
concentration. In every group considerable inter-individual variability was 
seen. Correction for body weight resulted in an improved correlation between 
daily bromide dose and increase in concentration (r=0.78, p<0.01). 
Conclusions Unfortunately, the inter-individual variability in clearance of 
bromide was considerable. This limits the use of bromide to primarily measuring 
adherence in individual patients during long term follow-up. Bromide appears to 
be a potentially useful marker to be added to drugs for assessment of individual 
adherence to long term drug therapy. This needs to be investigated in various 
patients, particularly for patients with relatively asymptomatic diseases (e.g. 
hypertension).
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Introduction
Adherence to prescribed drug therapy is very important both in clinical practice 
and in studies on effects of drugs. About one-third or more of patients adhere 
poorly with prescribed regimens.1,2 Adherence to a prescribed drug regimen has 
been found to decrease over time, and also declines between clinic visits.3  Non-
adherence appears to occur irrespective of the type of disease or its prognosis.2 
Adherence is a very difficult subject to study.4 The subjective assessment of 
adherence by either patients or doctors is notoriously unreliable. Pill counting 
is often used, but does not accurately reflect actual intake of pills and correct 
timing of intake. It often overestimates drug intake.2,5 Electronic registration 
using recording devices for monitoring medication intake (MEMS) is excellent 
in monitoring times of opening the pill bottle, but does not measure actual 
intake of the drug. Several markers have been added to the study drug to assess 
adherence, these include bromide, digoxin, phenobarbitone and isoniazid or its 
metabolites, acetylisoniazid and isonicotinic acid.6-9 As adherence is particularly 
an issue with chronic therapy, an ideal marker should have a half-life over 3–4 
days. Isoniazid and its metabolites could well be measured in urine, but their 
half-life is short (1 and 4 h, respectively), so these markers can only assess 
adherence over a short period of time. Digoxin has a longer half-life of about 
60 h.7 Phenobarbitone has the disadvantage of causing mild sedation in higher 
doses.8 Bromide is readily absorbed throughout the gut, almost exclusively 
distributed in the extracellular space and innocuous if used in small doses.10 
Its half-life is long, about 12 days.10 Because of these characteristics bromide 
may be a suitable marker of drug adherence, in particular in chronic diseases. 
Therefore, in the present study the (pharmacokinetic) properties of potassium 
bromide were further investigated.
Methods
The study was approved by the Hospital Ethics Committee, and all participants 
gave written informed consent before inclusion. In total, 24 healthy volunteers 
participated in the study. At baseline, weight, height and creatinine clearance 
(using 24-h urine collection) were measured. The participants were randomised 
in a double-blind fashion to three groups taking either 15, 24 or 30 mg of 
potassium bromide capsules once daily for 20 weeks. The maximum potassium 
bromide dose of 30 mg daily was chosen to allow for a detectable increase 
of the serum bromide concentration, while staying well below the serum 
levels associated with symptoms. Given the long half life of bromide it was 
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assumed that a daily potassium bromide dose of 15 mg would be equivalent 
to a situation of 50% adherence compared to a daily potassium bromide dose 
of 30 mg (provided that there was 100% adherence during the study). A daily 
dose of 24 mg of potassium bromide would then represent 80% adherence. Full 
adherence to once daily intake was therefore critical and monitored closely. 
The volunteers were continuously encouraged to be fully compliant. Blood 
samples for measurement of serum bromide concentration were taken twice 
at baseline, once every two weeks during the 20 weeks of potassium bromide 
intake, and 4 and 8 weeks after discontinuation. Adherence was monitored 
by capsule counting at each control visit and by Medication Event Monitoring 
System (MEMS)-devices throughout the study. These devices are pill-boxes that 
electronically record the date and time of each opening of the box.11 
Whole blood samples were centrifuged after collection and the sera were stored 
at −20°C until analysis. Bromide concentrations were determined using high-
performance liquid chromatography (HPLC) and pre-analysis ultrafiltration as 
described previously.12 In short, 1 ml of serum was pipetted in the reservoir 
of a Centrifree Micropartition Device (Amicon) and centrifuged at 2,000 g for 
60 min at 18°C. Subsequently, 10 μl of the clear ultrafiltrate was injected 
into the chromatographic system. This system consisted of an anion-exchange 
column (Whatman Partisil SAX 10 μm particles), an isocratic phospate-buffered 
mobile phase and ultraviolet detection at 195 nm. Plots of peak area versus 
concentration of the potassium bromide standards were used to calculate the 
amount of bromide in the samples. The standard curve was linear up to 3.0 
mmol/l (240 mg bromide/l). The between run coefficient of variation was 17% 
for a 0.04 mmol/l (3 mg/l) sample and 12% for a 0.10 mmol/l (8 mg/l) sample. 
The detection limit of the method was 0.01 mmol/l (0.8 mg/l). 
Pharmacokinetic analysis 
Bromide concentration-time data were analysed by noncompartmental 
methods, after correction for baseline values. The bromide half-life (t½) was 
determined by log-linear regression from the slope (β) of the elimination curve 
after stopping intake, by the equation ln 2/β. The steady-state concentration 
was obtained from the mean of the bromide concentrations measured over 
the period V7 to V9 (weeks 14 to 18). The apparent oral clearance (CL/F) was 
determined by dividing the dosing rate (dose/day) by the concentration at 
steady-state, and the apparent volume of distribution (V/F) by dividing Cl/F by 
β (where F represents the oral bioavailability). 
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Based on the assumption that all participants did indeed take the prescribed 
dose every day the average concentrations in the 24 mg daily and 15 mg daily 
group were used to determine bromide concentrations associated with 80% 
(24/30) and 50% (15/30) adherence, respectively. All analyses were done with 
and without correction for body weight to assess if variations of body weight 
would affect bromide concentrations.
Results
Twenty-four healthy volunteers participated in the study. Their baseline 
characteristics are shown in Table 1. There were no significant differences be-
tween the three groups. Table 2 shows the adherence to daily capsule intake 
as assessed by capsule counting and electronic registration. At each 2-weekly 
visit to the clinic, the number of tablets taken from the container was reg-
istered. This number can be compared to the number of container openings  
registered during the same period. The level of adherence was very high, over 
99%, in this highly motivated group of subjects. All participants completed the 
study, no side effects of bromide were noted. 
The mean bromide concentrations during potassium bromide intake for each 
dosage group are shown in Figure 1. 
Table 1.  Baseline characteristics of participants taking 15, 24 or 30 mg potassium bromide per day
Group 15 mg/day 24 mg/day 30 mg/day
n 8 8 8 
Age (years) 39±13 40±16 41±12
Weight (kg) 79±12 71±17 76±19
Height (cm) 174±10 172±13 169±8
Gender (male:female) 3:5 3:5 1:7
Creatinine clearance 92±16 89±16 90±13
(ml/min/1.73m2)a 
All data are presented as mean±SD, unless stated otherwise. 
aCalculated using 24-h urine collection
Table 2.  Adherence as assessed by capsule counting and electronic monitoring
Group Days Capsule Trackcap
                                          (total) counting (MEMS)
15 mg/day 1,109 1,109 1,108
24 mg/day 1,124 1,110 1,110
30 mg/day 1,091 1,090 1,079
All three groups 3,324 3,309 3,297
At 2-weekly intervals the number of capsules taken (measured using capsule counting and the 
electronic registration of container openings) was compared to the expected number, i.e. the number 
of days that had passed since the start of bromide intake. The total number of days varies slightly 
between the different groups because some subjects stopped taking tablets a few days earlier because 
of holidays
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At baseline, there were no differences in serum bromide concentrations 
between the three groups. During potassium bromide intake the bromide 
concentrations varied between groups. Six to ten weeks after the start of 
bromide the concentrations stabilised, suggesting a steady-state situation.
Pharmacokinetic data on bromide for each dose group are presented in Table 
3. There were no statistically significant differences in elimination half-life, 
apparent oral clearance and the apparent volume of distribution of bromide 
between the three groups. The steady-state concentration was significantly 
higher in both the 24 mg and 30 mg group when compared to the 15 mg group, 
and there was borderline significance between the 30 mg and 24 mg group 
(p=0.07). However, inter-individual variability in the apparent oral clearance 
was considerable within each of the three groups.
Figure 1.  Bromide-concentrations in subjects taking 15, 24 or 30 mg potassium bromide daily (n=8 
for each group). B1 and B2; baseline measurements. V1-V10; 2-weekly visits during bromide intake. 
Visit 1 (V1) is the first bromide measurement 2 weeks after starting with bromide intake. U1 and U2: 
bromide concentration measurement, 4 and 8 weeks, respectively, after stopping intake. Data are 
presented as mean±SE.
The mean increase of bromide concentrations was calculated by subtracting the 
mean of the two baseline results from the mean of the concentrations at visits 
7, 8 and 9. Figure 2 shows the mean increase of bromide-concentrations at visits 
7 to 9 (weeks 14 to 18) for the 24 subjects according to the bromide content of 
the capsules taken. The increases (mean±SD) in bromide concentrations were 
0.070±0.024, 0.125±0.039 and 0.185±0.068 mmol/l in the 15 mg, 24 mg and 30 
mg per day groups, respectively. The mean increase in the bromide concentration 
of the 15 mg group was significantly lower than in both other groups (p<0.01). 
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The difference in the mean increase of the concentrations of the 24 and 30 mg 
dose groups approached statistical significance (p=0.054) (Figure 2). For the 
increase in bromide concentrations, there was a considerable overlap between 
the three groups and there was considerable variation within each group. This 
makes it difficult to choose cut-off levels that adequately distinguish between 
the dosage groups. We hypothesised that body weight could be a confounding 
factor and corrected the results for body weight.
Figure 3 shows the increase of bromide concentration related to the dosage 
taken per kilogram (kg) body weight. There is a linear relationship between 
increase of bromide concentration and bromide dosage per kg body weight 
(Pearson coefficient of correlation 0.78, p<0.01). When 30 mg of potassium 
bromide per day is added to a drug that is prescribed for a long time, the drug 
adherence can be calculated from the increase in bromide concentration and 
the body weight, using the following formula that is derived from Figure 3:
  Adherence % = 7.33x {Increase in Br concentration (mmol/l) + 0.0188}x Body weight (kg)
Discussion
In the present study, we show that potassium bromide has pharmacokinetic 
characteristics that may make it a reliable and stable marker of adherence to 
prescribed drug therapy. The mean steady state concentration for each group 
of eight subjects directly depended on the amount of potassium bromide taken 
(Figure 1). The results of Figure 2 indicate that, although the bromide levels 
were clearly different between the dosage groups, there is still considerable 
overlap between groups due to inter-individual variability. Due to the variability 
in clearance between individuals, the use of bromide as a marker for adherence 
Table 3.  Steady-state pharmacokinetic parameters of bromide
Group 15 mg/day 24 mg/day 30 mg/day
Baseline concentration 0.07±0.004 0.07±0.02 0.07±0.02
(mmol/l)
Bromide t½ (days) 11.0±2.0 10.4±1.6 11.0±1.8
Steady-state 0.14±0.03 0.20±0.04a  0.26±0.07a,b  
concentration (mmol/l)
Cl/F (l/day)   2.0±0.7   1.7±0.5   1.6±0.7
V/F (l)    31±9    25±7    24±11 
Data are presented as mean±SD. Differences between groups are not significant unless stated 
otherwise. ap<0.01 versus 15 mg bromide/day. bp=0.07 versus 24 mg bromide/day. t½elimination 
half-life; Cl/F, apparent oral clearance; V/F, apparent volume of distribution; F, oral bioavailability
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is far less useful for patient groups than for individuals. Measuring bromide 
levels to assess adherence could therefore primarily be used for longitudinal 
observation in individual patients. This could be particularly helpful when 
there is a decrease of a therapeutic effect without changes in prescribed 
medication.
Adjustment of levels for body weight improved the correlation between dose 
and serum bromide, and thus allows for a better assessment of adherence 
(Figure 3). Based on the formula that we developed, it is possible to calculate 
thresholds for the increase in bromide concentration associated with good (i.e. 
80% or more) adherence in patients of different body weights. 
We preferred to investigate the use of a marker with a long half-life. Our 
purpose is to help identify nonadherence in patients with chronic conditions. 
Especially, we would like to identify patients who take their medicines but 
Figure 2. Mean increase in serum bromide concentrations in the 8 subjects of 
each group as measured at visit 7 to 9 (14 to 18 weeks)
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are also regularly non-adherent. This group of patients would probably best 
be accessible for improvement in adherence. We are less interested in short 
term changes in adherence for which markers with a shorter half-life would be 
more suitable. This can be compared to the situation in patients with diabetes 
mellitus, in whom Hba1c is used as a marker for long-term glycaemic regulation. 
In patients with normal recent glucose levels, but a high Hba1c, insufficient 
adherence over a longer term needs to be considered. 
Using markers with a long half-life may provide an accurate assessment of 
adherence over a longer period. On the other hand, the disadvantage of using 
such a marker is that non-adherence in the week before the blood sample 
was taken may not be detected. However, 'drug-holidays' generally occur 
between clinic visits, while adherence increases when an appointment date 
is approaching (referred to as the so called 'white-coat adherence'). In this 
situation, use of a marker with a short half-life may in fact overestimate long-
term adherence.3 
One area where long-term adherence is important is treatment of hypertension, 
where non-adherence is highly prevalent. Use of bromide may help raise 
consciousness of the importance of adherence, and help both the physician 
and the patient to address adherence issues. 
Bromide appears to be well tolerated, and its half-life of about 11 days makes 
Figure 3. Relationship between the bromide dosage taken per kg body weight and 
the increase in bromide concentration (calculated as the mean of the increases at 
visits 7 to 9 (weeks 14 to 18))
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it a useful marker for long term adherence. A limitation of our study could be 
that we did not actually test the effect of skipping daily doses. Instead, we 
studied the effect of 80% and 50% decrease in dose of the daily taken potassium 
bromide capsule. However, given the long half-life of bromide, it is not likely 
that this would have affected the results. Using a marker like bromide clearly 
also has some other disadvantages. Adherence to only one drug at a time can 
be tested and short term changes in adherence will not be detected. Also, no 
information is obtained concerning the pattern of adherence, so it is unknown 
if the patient is taking the tablets at the prescribed regular intervals or at a 
more random pattern. We suggest that adherence can best be assessed by a 
combination of bromide as a marker and the use of electronic registration 
(MEMS pill boxes). In addition, this monitoring of the adherence requires blood 
sampling, probably at least once every 6 weeks during drug intake.
Pharmacokinetic aspects of bromide
The oral bioavailability of bromide is about 95% and the elimination half-life 
12 days.13 Bromide is not bound to plasma protein or sequestered in cells; 
it occupies the same volume of distribution as chloride and competes with 
that ion for excretion by the kidney.10 Because bromide is excreted by the 
kidney, serum bromide concentrations will be expected to be higher in patients 
with renal insufficiency. However, for the amounts of potassium bromide given 
in the current study, toxic concentrations are not expected to occur even in 
renal insufficiency, although caution in these patients is of course warranted. 
Normal values for bromide in relation to the severity of renal insufficiency are 
not available. In patients with chloride depletion the clearance of bromide is 
markedly reduced. Until further studies have determined the specific effects of 
impaired renal function and the effect of diuretics on bromide clearance and 
steady state levels, the currently proposed formula for assessment of adherence 
based on bromide concentrations should not be used in these patients.
The safety of bromide as a marker
Bromide was discovered in 1826 by Balard and since then has been used in 
various preparations as sedative and anticonvulsant.10 Before the discovery of 
phenobarbitone as an anti-epileptic drug in 1912, potassium bromide was the 
only known effective agent to treat epilepsy.14 Table salt is the major source of 
dietary bromide.10 Van Gelderen et al.15 proposed a no-effect level (NOEL) of 4 
mg sodium bromide/kg body weight (equivalent to 4.6 mg potassium bromide/
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kg). Sangster et al.16 also showed that administration of different dosages of 
bromide up to 9 mg/kg/day for a period of 12 weeks was safe. The mean 
intake of potassium bromide in our group of 24 healthy volunteers was 0.32 
mg/kg (±0.11; range 0.16–0.48), which is well below the NOEL. Baseline blood 
concentrations of bromide are 3–4 mg/l (0.0375–0.05 mmol/l).17 The highest 
concentration of bromide that we measured (34 mg/l; 0.43 mmol/l) was well 
below the levels that are associated with complaints (500–1,000 mg/l; 6.3–12.5 
mmol/l) or toxicity (>2,000 mg/l; 25 mmol/l).
Safety of potassium
The usual daily intake of potassium is 40–120 mmol (1 mmol/kg/day).18 The 
amount of potassium administered daily amounts to 0.25 mmol when taking 30 
mg of potassium bromide. This amount is therefore negligible compared to the 
usual daily amount of potassium taken. 
Conclusion
Assessment of adherence should be a daily topic in every patient–doctor 
consultation. Efforts should be made to increase awareness of the consequences 
of non-adherence (both clinically and economically). The results of this study 
suggest that low-dose bromide, despite its limitations, may be used to improve 
reliable assessment of adherence. Further studies need to assess its use in 
clinical trials and practice.
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Abstract
Introduction  Adherence to prescribed antihypertensive medication is essential 
for adequate long term control of blood pressure (BP) in hypertensive patients. 
We performed a study to compare different methods of measuring adherence 
and to investigate the relation between adherence and effect of treatment 
with trandolapril 2 mg/verapamil SR 180 mg on BP in patients inadequately 
controlled with one antihypertensive drug.
Methods  Patients were included if BP was insufficiently controlled (diastolic 
blood pressure (DBP) > 95 mmHg and/or systolic blood pressure (SBP) > 160 mmHg) 
on monotherapy. At the start of the study antihypertensive medication was 
stopped. After a placebo period of 4 weeks, treatment with trandolapril 2 mg/
verapamil SR 180 mg was started. The effect on BP was determined throughout 
the study period using a mercury sphygmomanometer and ambulatory blood 
pressure monitoring (ABPM, SpaceLabs 90207). Adherence was measured using 
three methods: capsule counting, electronic registration of pill-box openings 
(Medication Event Monitoring System, MEMS) and by measuring serum bromide 
concentrations. Potassium bromide (30 mg) had been added to each capsule 
of trandolapril 2 mg/verapamil SR 180 mg. Changes in bromide levels were 
compared to the previously measured change in serum bromide in volunteers 
taking 24 mg bromide daily (simulating 80% adherence).
Results Thirty patients participated in the study, 14 men and 16 women. 
Treatment with trandolapril 2 mg/verapamil SR 180 mg for 20 weeks lowered 
office BP by 9.6/7.5 (± 11.4/6.4) mmHg. ABPM also showed a significant 
decrease in SBP and DBP after 8 and 16 weeks of treatment. 
Adherence as assessed by capsule counting, MEMS and measurement of bromide 
concentration was good for the majority of patients. The serum bromide 
concentrations indicated good adherence in 93% of patients at weeks 12 and 
20. Adherence was highest when assessed by capsule counting. Results for 
electronic monitoring and adherence based on bromide measurements were 
comparable.
Conclusion  Measuring serum bromide levels may be suitable for assessment 
of adherence to drug therapy. However measuring bromide is a rather time-, 
cost- and work-consuming method for determining adherence.
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Introduction
Hypertension is one of the most important risk-factors for cardiovascular 
morbidity and mortality. In general, high blood pressure (BP) responds well 
to drug treatment. However, it is often challenging for patients to take 
antihypertensive drugs for many years, especially if drug intake is associated 
with side effects while the increased BP itself is asymptomatic.
Adherence to a medication regimen, defined as the extent to which patients 
take prescribed medications,1 is a major factor determining the success of 
hypertension treatment. In chronic conditions, including hypertension, 
adherence to prescribed drug regimen is often low. Adherence rates are higher 
in clinical trials for chronic conditions, but even in these trials adherence rates 
of 43 to 78 percent have been reported.1 Adherence is difficult to measure and 
although several methods have been described and tested,1 objective methods 
to measure drug-adherence are needed. We have previously documented that 
potassium bromide has pharmacokinetic properties that may make it an useful 
marker to estimate drug intake.2 
Aim of the present study was to examine whether bromide addition to an 
antihypertensive drug with measurement of serum bromide is a better measure 
of therapy adherence than electronic monitoring of drug intake.
Patients and methods
Hypertensive patients were recruited via advertising in local newspapers and 
were included after written informed consent. Patients were included if they 
had a diastolic blood pressure (DBP) ≥95 mmHg and/or a systolic blood pressure 
(SBP) ≥160 mmHg despite at least four weeks of antihypertensive monotherapy. 
Patients were informed that the purpose of the study was to see if BP could be 
adequately lowered with a combination of two antihypertensive drugs. They 
were not informed that the study was actually designed to assess adherence 
to drug therapy, as this would possibly affect study outcome. The study was 
approved by the Hospital Ethics Committee.
Antihypertensive medication was stopped at the start of the study. Patients 
received a placebo for four weeks and then treatment with the combination of 
the angiotensin converting enzyme inhibitor trandolapril 2 mg and the calcium 
antagonist verapamil SR 180 mg once daily was started and continued for 20 
weeks. This combination was given in one capsule and to each capsule 30 mg 
potassium bromide was added. Office blood pressure (OBP) was measured every 
two weeks during the placebo period and at weeks 2, 4, 8, 12, 16 and 20 of the 
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treatment period. Ambulatory blood pressure monitoring (ABPM) was carried 
out three times: two weeks after starting placebo and 8 and 16 weeks after 
start of active drugs.
OBP was measured using a mercury sphygmomanometer after patients had 
been resting in sitting position for 10 minutes, with the back supported and the 
arm on the desk. The average of three BP readings was calculated. ABPM was 
carried out using a SpaceLabs 90207. Measurements were performed every 20 
minutes during the day and every 30 minutes during night time. Trough (T) BP 
was calculated as the mean SBP and DBP within a window of one hour before 
and half an hour after drug intake at the end of ABPM. Within each 1 hour 
time frame during the nine hours after study drug intake, the mean SBP and 
DBP were calculated. The lowest SBP and DBP of all 1 hour time frames were 
determined and were defined as the peak BP (PBP), i.e. the BP level at the time 
of largest drop in BP. 
Adherence with prescribed drug regimen was measured using three methods: 
capsule counting, an electronic “track cap” system (Medication Event Monitoring 
System, MEMS), and measuring serum bromide concentration. Adherence based 
on capsule counting was measured by dividing the number of capsules taken 
(calculated as dispensed minus returned number of capsules) by the expected 
number of capsules taken, defined as the number of days within the period, first 
day (container handed over) included, last day (container taken in) excluded. 
A container with 40 placebo capsules was handed out at the start of the study 
and taken in at week 4 of the placebo period. A container with 100 capsules 
of trandolapril 2 mg/ verapamil SR 180 mg was handed out at the end of the 
placebo period and taken in at week 12 of the treatment period. A second 
container with 70 capsules was handed out at week 12 and taken in at the end 
(week 20) of the treatment period. Adherence was defined as “good”, when 
the drug intake was ≥80% based on capsule counting.
The second method for measuring adherence was electronic monitoring. Using 
a special container the number, time and date of each opening of the container 
was registered. As one capsule should be taken every day it was expected that 
the container was opened once daily. Adherence was calculated as the number 
of times the container was opened divided by the number of days the capsules 
should have been taken. It was defined as “good” when adherence was ≥80% 
based on electronic monitoring.
The third method for assessment of adherence was measuring serum bromide 
concentrations. All drug capsules (but not the placebo capsules) had been 
supplemented with 30 mg of potassium bromide. Blood samples for bromide 
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levels were taken at clinic visits throughout the study period: every two weeks 
during the placebo period and at weeks 2, 4, 8, 12, 16 and 20 of the treatment 
period. Recently we studied the pharmacokinetic properties of bromide 
in a group of 24 healthy volunteers using different amounts of potassium 
bromide.2 
The mean increase in bromide level in the eight volunteers taking 24 mg 
potassium bromide daily was used as cut-off level for 80% adherence: values 
above this concentration were considered indicative of good adherence, 
whereas values below this level were considered as poor adherence. 
A prespecified secondary outcome was the number of patients in whom the 
office BP normalised and/or responded to treatment with the antihypertensive 
drug combination. Normalisation of DBP was defined as a decrease of DBP to a 
level equal to or lower than 90 mmHg. Patients were identified as a 'responder' 
when BP normalised or when the decrease in DBP was at least 10% of baseline 
BP (placebo period).
Normalisation of SBP was defined as a decrease of SBP to a level equal to 
or lower than 140 mmHg. Patients were identified as a 'responder' when BP 
normalised or the decrease in SBP was at least 10% of baseline BP (placebo 
period).
For ABPM, normalisation of DBP was defined as a decrease of daytime DBP to 
a level equal to or lower than 85 mmHg and for SBP as a decrease of daytime 
SBP to a level equal to or lower than 135 mmHg. Patients were identified as a 
'responder' if BP normalised or if the decrease in DBP, respectively SBP was at 
least 10% of baseline BP (placebo period). Daytime was defined as the period 
between 10.00 hours a.m. and 8.00 hours p.m. 
Statistical analysis
Results were analysed using Student’s t-test. Differences with a p-value 
<0.05 (two-sided) were considered statistically significant. Correlations 
were calculated by using the Pearson’s coefficient of correlation. Results are 
presented as mean ± SD, unless indicated otherwise.
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Results
Thirty patients, 14 men and 16 women, participated in the study. Baseline 
characteristics are shown in Table 1. One patient discontinued the drug in week 
2 of the treatment period because of a maculo-papular skin reaction. Another 
patient discontinued treatment at week 16 because of dramatic personal 
events not related to the study or drug-intake. No serious adverse effects were 
reported.
The results for measuring adherence by the three methods are shown in Table 2. 
Based on capsule counting almost all patients showed good adherence (intake 
≥80% of expected) over the whole 20 week treatment period. One patient 
returned the container two weeks after the last visit and was considered to be 
non-adherent. According to electronic monitoring adherence was “good” (at 
least 80% of expected openings of the drug container) for all patients except 
for 2 patients during the second treatment period (between 12 weeks and 20 
weeks of treatment). Two other patients were considered to be non-adherent 
because recordings were missing after the last visit.
The bromide concentration increased from 0.06±0.01 mmol/l at baseline to 
0.26±0.06 mmol/l (mean of bromide concentrations at weeks 12, 16 and 20 
of treatment period). The change in bromide concentration for the individual 
patients during the treatment period is shown in Figure 1. The mean of the 
change in bromide concentration of the hypertensive patients after 12, 16 and 
20 weeks of treatment was 0.21 ± 0.01 mmol/l (standard error, SE).
In a previous study we demonstrated that the increase in serum bromide levels 
in a defined dose of potassium bromide of for example 30 mg, negatively 
correlates with body weight.2
Table 1.  Baseline characteristics of patients (mean ± SD are given).
 Mean  (± SD)
age (yrs)    53  (±10)
height (cm)  171  (±7)
body-weight (kg)    82  (±13)
BMI (kg/m2)      27.9    (±4.6)
heart rate (bpm)     76  (±12)  
blood pressure (mmHg)          Office SBP         Office DBP
- at start of placebo period 151 (±13) 101 (±4)
- at week 2 of placebo period 159 (±15) 105 (±5) 
- at week 4 of placebo period 158 (±15) 105 (±5)
SBP, systolic blood pressure; DBP, diastolic blood pressure; bpm, beats per minute.
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This was confirmed in the current study, the coefficient of correlation between 
body weight and change in bromide concentration was –0.53 (Figure 2). As 
shown in Figure 2 there was a linear relationship between the dose of potassium 
bromide administered per kilogram body weight and the mean increase in 
bromide concentration (for weeks 12, 16 and 20).
For comparison with the other two methods for assessment of adherence, we 
used the increase in bromide levels measured at weeks 12 and 20 of treatment 
(Table 2). Adherence based on the measurement of serum bromide was 'good' 
for 93% of participants at both time points. The two patients that were 
categorized as  'poor' adherent appeared to have a high body-weight: 91 kgs 
and 98 kgs, respectively. The patients that were identified as non-adherent by 
electronic monitoring and those identified by measuring serum bromide levels 
were not the same patients. For one patient with poor adherence based on 
serum bromide measurement, adherence was 82% during the second treatment 
period (weeks 12 to 20) based on electronic monitoring. But for the other 
patient the adherence rate was 102% at the second treatment period based on 
electronic monitoring. For all four patients that were found to be non-adherent 
Figure 1. Changes in serum bromide concentration in 30 patients treated with trandolapril/
verapamil. The broken lines indicate patients with good adherence. The two patients with poor 
adherence are shown (solid lines, open triangles). On the right side of the figure the mean change in 
bromide concentration (± 2SE) are shown for the volunteers (n=8)2 and hypertensive patients (n=29), 
both using 30 mg potassium bromide.
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based on electronic monitoring (two patients were classified as non-adherent 
because containers were missing at the last visit) adherence was good based on 
serum bromide measurements.
Blood pressure response following treatment with trandolapril/verapamil.
The results of office BP measurements are shown in Figure 3. Treatment with 
trandolapril 2 mg/ verapamil SR 180 mg for 20 weeks decreased OBP by 9.6/7.5 
(±11.4/6.4) mmHg (both p-values <0.05).
Results of ABPM are shown in Table 3. During the study period ABPM measurements 
were technically insufficient in three patients. Compared to baseline (visit 2), 
there was a significant decrease in systolic and diastolic BP, for mean, trough 
and peak BPs during treatment (Table 3).
Table 4 shows the number of  'normalisers' and  'responders' to treatment with 
trandolapril/verapamil. Using office measurements 29% of patients responded 
after 20 weeks of treatment with trandolapril/verapamil for DBP and 39% of 
patients for SBP. Results for patients that fulfilled criteria of 'normalisers' or 
'responders' for both SBP and DBP are also shown in Table 4.
Figure 2. Relationship between body weight and increase in bromide concentration (r=-0.53). The 
association between the mean increase in bromide concentration (weeks 12, 16 and 20) and the 
dose of potassium bromide per kilogram body weight is shown in the lower part of the figure.
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Discussion
In the present study, adherence with antihypertensive therapy was evaluated 
using three different methods: capsule counting, electronic monitoring and 
measuring serum concentrations of bromide, that had been added as a marker 
to the active drug. In general, adherence with drug therapy was good according 
to all methods. Several methods have been developed for assessment of 
adherence.1 All methods have advantages and limitations. Capsule counting is 
known to be less reliable as a method of measuring adherence, because its results 
can easily be influenced by the patient who can discard capsules.4 However 
it is one of the most simple methods to measure adherence.4 More recently 
electronic monitoring has been introduced, in which a special container is able 
to record time and date of each container opening.1,5,6 Electronic monitoring is 
an accurate method of measuring adherence. A patient would consistently have 
to open and close the pill container without taking medication to circumvent 
this method. However, both capsule counting and electronic monitoring do 
not document the actual intake of chronically used drugs. To overcome this 
particular disadvantage, markers have been added to the drugs and the marker 
concentrations have been used to measure adherence. In the past low doses of 
digoxine, phenobarbitone, phenobarbital and bromide have been used.7-10 This 
study confirms that bromide is potentially suitable as a marker for adherence 
as has previously been shown, because of its long half life (about 12 days) and 
because it is not associated with side-effects in the small dosages used.2 The 
mean of the change in bromide concentration of the hypertensive patients in the 
Figure 3. The course of the office blood pressure during the study period (mean ± SD).
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current study was comparable to the mean increase in bromide concentration 
observed in the eight volunteers taking 30 mg potassium bromide (0.21 ± 0.01 
mmol/l versus 0.18 ± 0.02 mmol/l, Figure 1).2
Although measurement of bromide added to the antihypertensive drug confirms 
actual drug intake, there are also disadvantages. Multiple blood samplings 
are necessary and the method is quite time-, cost- and work-consuming. 
Another  disadvantage is that it can only monitor intake of one drug or a fixed 
combination of drugs in one capsule. The inter-individual variation in the serum 
bromide levels is quite large (Figure 1). 
Measuring serum bromide levels seems therefore to be most useful as a method 
to follow-up adherence in an individual patient. Its main application probably 
would be as a research tool in situations in which actual drug ingestion over 
longer time periods has to be confirmed.
In this small study all three methods of measuring adherence appeared to 
give similar results. Not surprisingly capsule counting was associated with 
the highest level of adherence. By using electronic monitoring and measuring 
serum bromide levels non-adherent patients could be identified. However these 
were not the same patients for the two methods. The non-adherent patients 
identified by measuring serum-bromide levels had a high body weight. As was 
previously shown the increase in bromide level correlated negatively with body 
weight (Figure 2).2 
 
Table 2.  Assessment of adherence by three different methods.
Method n Number adherent n Number adherent
  at 12 weeks of  at 20 weeks of
  treatment period (%)  treatment period (%)
Capsule counting1)
'Good' adherence  29          29 (100)  28          27  (96)
Electronic monitoring2) 
'Good' adherence  29          29 (100)  28          24  (86) 
Serum bromide level       
'Good' adherence  29          27 (93)  28          26  (93)      
n, number of patients. For all methods: one patient withdrawn at week two of treatment period, 
one patient at week 16. 1) One patient returned container two weeks after last visit, this patient was 
considered to be non-adherent. 2) For two patients track cap recording was missing at last visit 
(week 20). These patients were considered to be non-adherent. Also two patients were found to have 
an adherence rate less than 80%.
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Several factors may have contributed to the very high adherence in this 
patient group. First, patients were selected via advertising in local media. This 
probably resulted in self-selection of a highly motivated group of hypertensive 
patients. This is also demonstrated by the fact that adherence did not decrease 
substantially over the 20-week study period in contrast to the results of other 
studies.3 As overall adherence was very high for all thirty patients, it can 
be expected that correlating the level of drug adherence to the efficacy of 
drug therapy (the decrease in BP) is less informative. Actually there was no 
correlation between the change in mean arterial pressure from visit 3 (start of 
treatment period) to visit 9 (week 20 of the treatment period) and the change 
in serum bromide concentration.
Second, although the patients were not aware that assessment of adherence 
was the most primary objective of this study, they were aware of participation 
in a clinical trial, and the rate of adherence with drug therapy is usually higher 
in clinical trials. Third, combination therapy of two drugs was given in the 
simplest form (one pill, once daily), and it is known that adherence to drug 
therapy is inversely proportional to frequency of dose.11 Fourth, the frequency 
of clinic visits (every 2-4 weeks) was much higher than in usual clinical care, 
Table 3. Results of Ambulatory Blood Pressure Measurements 
Week Number SBP (mmHg) DBP (mmHg)
   Mean (±SD) Mean (±SD)
2 of placebo period        25 146.2 (±13.9) 92.7 (±8.4)
8 of treatment period        25                135.4 (±12.8)a) 85.0 (±7.7)a) 
16 of treatment period        25 135.8 (±11.6)a) 85.5 (±8.0)a)
   Trough BP   
2 of placebo period                25  145.4 (±19.5) 92.7 (±13.7)
8 of treatment period        25 133.8 (±16.3)a) 84.2 (±11.2)a)     
16 of treatment period        25 134.2 (±12.9)a) 86.4 (±11.7)a)
   Peak BP
2 of placebo period        25  138.5 (±13.8) 86.8 (±9.4)
8 of treatment period        25 125.1 (±16.8)a) 76.1 (±11.3)a)     
16 of treatment period        25 125.7 (±13.3)a)  78.1 (±10.8)a)
   Trough/Peak ratio*)
2 of placebo period       25 1.049 1.069
8 of treatment period    25 1.077 1.117
16 of treatment period       25 1.076 1.120
SBP, systolic blood pressure; DBP, diastolic blood pressure. *) T/P ratio was calculated by dividing 
trough value by peak value. a) p<0.05 versus week 2 of placebo period. Two patients were withdrawn 
during the study period and therefore excluded from the analysis. An additional three patients were 
excluded because of inadequate ambulatory blood pressure measurements for peak and trough blood 
pressures.
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and studies have demonstrated that patients usually improve their medication 
taking behaviour in the five days before and after a clinic visit (also referred to 
as white-coat adherence).12 
Finally, implicit in the study design was handing out the medication at the 
clinic visit by the physician, which removed the need for a special visit to a 
pharmacist as a potential barrier for good adherence. 
As overall adherence was very high for all thirty patients, it can be expected 
that correlating the level of drug adherence to the efficacy of drug therapy (the 
decrease in BP) is less informative. Actually there was no correlation between 
the change in mean arterial pressure from visit 3 (start of treatment period) 
to visit 9 (week 20 of the treatment period) and the change in serum bromide 
concentration.
Measuring adherence with several methods is difficult to do in clinical practice. 
For general clinical practice measuring bromide is too time-, cost- and work-
consuming. Electronic monitoring is a reliable and less complex method 
of measuring adherence. However, in clinical trials adequate assessment 
of adherence is critical for proper evaluation of study outcomes. Therefore 
in research studies, the combination of several methods may be helpful in 
avoiding the disadvantages inherent to each individual method.   
Office BP Normalisers Responders
week    n SBP      % DBP      % both   % SBP     % DBP      % both    %
2 29 10 34 3 10 3 10 13 45 6 21 5 17
4 28 7 25 2 7 0 0 10 36 7 25 3 11
8 29 7 24 4 14 2 7 10 34 5 17 4 14
12 29 7 24 1 3 1 3 9 31 4 14 3 10
16 28 8 29 2 7 1 4 11 39 6 21 3 11
20 28 7 25 4 14 2 7 11 39 8 29 5 18
Table 4. Number and percentage of normalisers and responders for office blood pressure (see text 
for definitions) and daytime ambulatory blood pressure measurements (see text for definitions) 
during treatment period. Results are shown for systolic and diastolic blood pressure (SBP, DBP) 
separately and together (both). Office measurements for one patient were missing at week 4, two 
patients were withdrawn during the study period.
ABPM Normalisers Responders
week    n SBP      % DBP      % both   % SBP     % DBP      % both    %
8 28 10 36 9 32 6 21 17 61 15 54 12 43
16 28 9 32 8 29 6 21 13 46 15 54 11 39
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In conclusion, all three methods indicated good overall adherence with 
prescribed drug therapy. The results of assessment of adherence were fairly 
similar for the three methods in most patients. In this study bromide was not 
better than electronic monitoring for measuring adherence. Bromide can have 
a place when definite ingestion of the drug has to be known. The long half 
life of bromide makes it a potentially suitable marker for drug adherence in 
patients with asymptomatic conditions like hypertension. However because 
measuring bromide is relatively time-, work- and cost-consuming it is probably 
best used as a research tool. Electronic monitoring is a better candidate for 
application in everyday clinical practice.
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PART I: 
METHODOLOGICAL ASPECTS OF BLOOD PRESSURE MEASUREMENT
The diagnosis of hypertension depends on accurate blood pressure (BP) 
measurement. The consequence of inaccurate measurements could be 
unnecessary treatment of individuals incorrectly diagnosed as hypertensive, 
accompanied by possible adverse effects of drug treatment. Conversely 
inadequate BP measurement may increase cardiovascular risk in hypertensive 
patients who remain untreated.
The mercury sphygmomanometer is still the gold standard for BP measurement, 
but has to be replaced by other BP measuring devices due to the environmental 
hazard associated with mercury. Devices based on the oscillometric principle 
are good candidates to replace the mercury sphygmomanometer. They 
determine systolic and diastolic BP intrinsically different from mercury 
sphygmomanometry. The oscillometric technique uses algorithms (which are 
sometimes changed) to calculate systolic and diastolic BP, which are not made 
public by the manufacturer. 
Validation of BP measuring devices
Before using a BP measuring device in clinical practice one has to be sure that 
its accuracy is adequate. For this purpose a number of validation protocols 
has been developed.2-4 In chapters 2.1 and 2.3 of this thesis it is shown that 
despite the existence of a detailed protocol, two groups of investigators have 
interpreted the same guidelines of the protocol in a different manner, resulting 
in different validation results for the same device. Therefore, one always has 
to consider whether validation has been performed correctly.
In the recent International Protocol for the validation of BP measuring devices, 
nine sequential same-arm measurements are recorded, using the test-
instrument and a mercury sphygmomanometer.2 These sequential measurements 
have their drawbacks. BP is known to be variable, which may lead to different 
readings when a patient’s BP is measured sequentially even in a short period 
of time.2,3,5 Therefore we questioned whether there would be a better method 
to determine the accuracy of a BP measuring device. It would be best to 
measure BP simultaneously with the device to be tested and the reference 
device at one arm. For oscillometric devices this is often impossible. Most 
oscillometric devices deflate stepwise, making simultaneous measurements 
1
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with the mercury sphygmomanometer inaccurate.6 Some devices do not inflate 
the cuff sufficiently to be able to hear the first Korotkoff sound for determining 
systolic BP. In addition cuff pressure is frequently released too rapidly after the 
device has detected the diastolic BP, so that phase 5 of the Korotkoff sounds 
cannot be heard accurately.6 Many devices produce disturbing sounds which 
make accurate auscultatory measurements even more difficult. Simultaneous 
measurements at both arms can be considered as an alternative. Unfortunately, 
Atkins et al. showed that inter-arm difference can vary substantially in the 
same patient.6 This makes this approach not suitable.
Intra-arterial measurements, simulators or an accurate oscillometric device 
can be considered to replace the mercury sphygmomanometer as gold standard 
during validation studies. Intra-arterial measurements have been advocated 
by the Association for the Advancement of Medical Instrumentation (AAMI).4 
However, simultaneous same-arm measurements are not possible when intra-
arterial measurements are used as the reference. Using both arms has the 
same disadvantages as encountered with the mercury sphygmomanometer as 
the gold standard. The second option is more promising. A simulator is a device 
which simulates different BPs by reproducing oscillometric waveforms. They 
have the advantage of being objective because there is no observer bias. A 
disadvantage may be that the oscillometric pulses generated by the device 
may differ from physiologically occurring pulses.7 This approach was recently 
used to test the accuracy of two devices.8 The results were different from 
those previously obtained in clinical validation studies. Nevertheless the use of 
simulators is worth further investigation.
Another oscillometric device was used as a reference in our study described 
in chapter 2.4. Before considering such a device as a reference, it has to be 
validated and proven to be accurate. In our study grading results were the same 
irrespective whether the mercury sphygmomanometer or the oscillometric 
device were used as a reference. The advantage of this method is that only 
two observers are needed instead of the three observers needed according 
to the International Protocol.2 Because the measurements with the reference 
device are automated, observer bias is avoided. This method deserves further 
exploration.
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The oscillometric technique and its accuracy at higher blood pressure 
levels
Automated oscillometric devices were originally developed to measure the 
mean arterial pressure, for instance during surgery. Oscillometry can be used 
to determine the mean arterial pressure accurately, because this pressure 
corresponds to the point of maximal oscillations.10-11 When Geddes et al. 
defined thresholds for cuff pressure oscillations which would indicate the 
corresponding systolic and diastolic BP12, they found considerable variability for 
these thresholds between individuals. As stated before with the oscillometric 
technique systolic and diastolic BP are not actually measured but calculated 
based on an algorithm. Each manufacturer uses its own algorithm and depending 
on the algorithms used some devices may be more accurate than others. 
Nevertheless, irrespective which algorithm is used, the oscillometric technique 
itself will always have its limitations in determining systolic and diastolic BP.
Another issue of concern is the influence of higher BP levels on the accuracy 
of oscillometric BP measuring devices. In chapter 2.5 the accuracy of the 
oscillometric devices was shown to decrease at increasing BP levels, but this 
could well be an apparent decrease instead of a real decrease. The increased 
BP variability in hypertension as shown by Mancia et al., can also be a factor 
explaining the decreasing accuracy at higher BP levels.13 During the validation 
process several BP measurements are made during a time period, in which the 
patient’s BP will fluctuate. These fluctuations are higher at higher BP levels. 
It can therefore be expected that the accuracy of BP measuring devices is 
underestimated at higher BP levels, when sequential measurements are used 
during validation. Simulators might be a solution to test the influence of higher 
BPs on a device’s accuracy. 
It is important to report the accuracy of a device at different BP levels as mean 
± standard deviation. The this was not explicitly stated in the new International 
Protocol.2 Contrary to the use of Bland Altman plots, this gives the opportunity 
to compare devices more easily. In chapters 2.3 and 2.4 the accuracy at 
different BP levels was reported for the Welch Allyn Vital Signs Monitor and the 
Omron RX-M.
Which BP measuring device should be chosen in clinical practice?
Aneroid devices are introduced in many hospitals and in primary care as a 
substitute for the mercury sphygmomanometer. These devices have been 
shown to become inaccurate in time14-16 and should therefore only be used 
when a proper maintenance protocol is followed.16 
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The only alternative is an automated oscillometric device. As we stated 
before only devices that have been shown to be accurate according to a well 
performed validation study, should be considered. The current European 
directive on medical devices states that a medical device has to be safe. The 
specific section about devices with a measuring function states 'Devices with 
a measuring function must be designed and manufactured in such a way as to 
provide sufficient accuracy and stability within appropriate limits of accuracy 
and taking account of the intended purpose of the device. The limits of 
accuracy must be indicated by the manufacturer'.17 Although both BP measuring 
devices  that we have tested obtained a CE mark, they did not achieve grade 
A or B, which is needed for clinical recommendation (chapters 2.3 and 2.4). 
The European directive is not specific enough as it leaves the manufacturer 
free to decide which level of accuracy is sufficient. Therefore the directive 
should be changed in such a manner, that manufacturers are forced to have 
their devices tested independently according to an internationally accepted 
validation protocol before receiving a CE mark. The results of this independent 
validation should be documented in the user’s manual of the device. Every 
change of a device, like for example update of software, should be clearly 
indicated by the manufacturer by a change in model number.
Advantages of oscillometric devices
Despite the previously mentioned concerns the use of automated oscillometric 
devices has several advantages. They can measure BP automatically at 
programmed time periods and results can be stored. Other advantages are that 
observer bias, systematic errors and terminal digit preference are no longer an 
issue with the use of oscillometric devices.18-20 Because these devices are easy 
in use, patients can measure their BP at home. This can provide the physician 
with more measurements than the office readings alone, resulting in a better 
interpretation of BP during the day and also help to diagnose white-coat 
hypertension and masked hypertension.22 Preferably devices equipped with a 
memory should be used, because Mengden et al. showed that patients omitted 
BP readings from their logbook.22 Self-measurement of BP can help to improve 
adherence to drug therapy in hypertensive patients, as they can follow the 
effect of therapy on their BP. 
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How to interpret self-measured BP levels?
Because the automated oscillometric devices are easily available general 
practitioners and other physicians are more and more confronted with patients 
who self-measure their BP. Before interpreting the results it is important to 
ask which device has been used and to check if this device has been found 
accurate in properly performed validation studies, because the number of 
validated devices is quite small compared to the large number of devices 
commercially available.18,23,24 In chapters 3.1 and 3.2 an overview is given for 
devices measuring BP at the upper-arm and at the wrist. Also at http://www.
dableducational.com an up-to-date list of validated devices can be found. 
Moreover, one should consider if the device is equipped with a memory to 
store the results, or that these need to be written down with the possibility 
of omitting results. The physician should check whether the patient has 
sufficient knowledge about the procedure of BP measurement. Dietary factors, 
body position, patient preparation, timing of BP measurement, cuff size, arm 
position and site of measurement, all influence BP level independent of the 
kind of device.18 It is important that several measurements are performed after 
an adequate period of rest with the patient seated in a comfortable chair in 
a quiet room.19,20 Self-measurement should therefore only be performed after 
careful instruction. According to the recent recommendations by the Working 
Group on BP monitoring of the European Society of Hypertension, BPs should 
be measured twice in the morning and twice in the evening for one week. For 
long-term observation this should be repeated every three months.25 
The physician must also be aware that thresholds for diagnosis of hypertension 
are not the same for self-measured BP compared to BP measured at the 
office,but are equal to the thresholds for mean daytime ambulatory blood 
pressure monitoring: 135/85 mmHg.25
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PART II: 
ADHERENCE TO ANTIHYPERTENSIVE DRUG THERAPY
Patients are treated lifelong to reduce the increased cardiovascular risk 
associated with hypertension. Because most patients with hypertension are 
asymptomatic, drug adherence is not optimal in many patients and frequently 
decreases over time. Hippocrates already warned physicians to be aware of 
patient non-adherence.26 In chapter 4.1 examples are shown of the influence 
of drug adherence on hypertension treatment. Wetzels et al. showed in their 
recent review that the relationship between drug adherence and BP control 
may be less robust than previously thought.27 Nevertheless good adherence is 
essential to achieve adequate BP control in general adherence to drug therapy 
has been shown to be associated with lower mortality.28
Objective measurement of drug adherence
Unfortunately, drug adherence is difficult to measure objectively. 'Medication 
Event Monitoring System' (MEMS) devices can be used to follow a patient’s 
drug taking behaviour over a prolonged period of time.29 These are pill-boxes 
which electronically record the date and time of each opening of the box. A 
disadvantage of the MEMS devices is that the registration of each opening does 
not ensure actual drug intake. Therefore, the use of a marker added to an 
antihypertensive drug could be an useful alternative. 
In chapters 4.2 and 4.3 the use of the anion bromide as such a marker is 
described. In the past bromide had already been used as a marker for drug 
adherence in patients taking an antacid.30 We investigated the pharmacokinetic 
properties of bromide as a marker in a group of healthy volunteers. The half 
life of bromide was shown to be sufficiently long to follow drug adherence for 
a longer time period. Subsequently we showed the usefulness of bromide as a 
marker for drug adherence in a group of 30 hypertensive patients. Adherence 
was also measured using MEMS devices and by counting tablets. The overall 
agreement of drug adherence based on bromide levels with MEMS data was 
good. Disadvantages of this method are that for the determination of the 
bromide level a venapuncture is needed and that the assay is rather time- and 
cost-consuming. Moreover, drugs to which potassium bromide has been added 
are not commercially available. Therefore, the use of bromide as a measure of 
drug adherence is limited to the research setting. However, for the individual 
patient in which drug non-adherence is suspected and MEMS fails to prove non-
adherence, it might be a useful technique.
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Improving drug adherence
Only few interventions are effective in increasing adherence to antihypertensive 
drugs.31 A simple method is to reduce the number of daily doses. Other options 
are motivational strategies, reminders, patient education and special dosing 
devices. To further investigate different strategies to increase drug adherence, 
there is a need for objective methods like the one described by us. 
Noticeably, hypertensive patients who self-measure their BP at home, were 
shown to be more drug adherent.32 Self-measurement with accurate BP 
measuring devices can therefore be an useful strategy to motivate hypertensive 
patients to be adherent and to improve BP control in these patients.
PRACTICAL IMPLICATIONS AND DIRECTIONS FOR FURTHER RESEARCH
Irrespective whether BP measurements are performed at home, in primary care 
or in hospital, only validated devices should be used. For self-measurement, 
devices equipped with a memory are preferred. The current situation that allows 
unvalidated devices on the market is unacceptable. The Dutch government 
should use its regulatory role to ensure that each device has been tested 
according to an internationally accepted validation protocol. Comparable to the 
situation for drugs, for each device a registration report should be introduced, 
permitting control of the validation process and the calculations performed 
during validation. The accuracy of a device should be given for different BP 
levels and when changes in software are made the serial number of a device 
should be changed.
Physicians should inform their patients about the possibility to measure their 
BP at home. They should stress that only few devices are recommendable. 
Moreover the BP measurement technique should be explained properly.
Physicians have limited methods to measure adherence reliably. Therefore, 
for example for those patients whose BP appears difficult to treat, the use of 
MEMS devices should be made more accessible. Bromide seems to be useful for 
follow-up of adherence in selected patients. Further research should focus on 
the development of a more easy-to-use marker, which can be used on a larger 
scale in daily practice.
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Samenvatting
Hypertensie of hoge bloeddruk is een veel voorkomende en belangrijke 
risicofactor voor het optreden van hart- en vaatziekten. Voor het 
vaststellen van hypertensie en vervolgen van patiënten met hypertensie zijn 
nauwkeurige bloeddrukmetingen van groot belang. De traditionele manier van 
bloeddrukmeting, die gebruikt maakt van een kwikmanometer en stethoscoop, 
moest verlaten worden enerzijds vanwege milieuaspecten en anderzijds omdat 
de kunst van een 'state-of-the-art' bloeddrukmeting steeds minder beheerst 
wordt en er steeds betere automatisch metende apparaten ter beschikking 
zijn gekomen. Verreweg de meeste van deze automatische apparaten meten 
de bloeddruk volgens het oscillometrische principe. Hierbij worden trillingen 
in de bloeddrukmanchet, die geregistreerd worden tijdens verlagen van de 
druk, gebruikt om de bloeddruk te bepalen. Feitelijk wordt bij deze methode 
de gemiddelde bloeddruk gemeten en met behulp van een rekenmodel de 
boven- en onderdruk berekend. In dit proefschrift wordt nader ingegaan op 
de nauwkeurigheid van een aantal van deze apparaten die werken volgens dit 
principe.
Bij vrijwel asymptomatische aandoeningen, zoals hypertensie, is therapietrouw 
vaak een probleem. Bij uitblijven van effect van de voorgeschreven 
bloeddrukverlagende medicatie dient onvoldoende therapietrouw dan ook 
te worden overwogen. Het ontbreekt de arts op dit moment aan objectieve 
methoden om de therapietrouw te meten. In het tweede deel van dit 
proefschrift wordt ingegaan op verschillende methoden die gebruikt kunnen 
worden om de mate van therapietrouw bij de behandeling van hypertensie 
te meten. Hierbij wordt met name ingegaan op het gebruik van bromide als 
marker voor de therapietrouw.
Er bestaan verschillende protocollen voor het testen van de nauwkeurigheid 
(validatie) van bloeddrukmeters. Ieder protocol heeft voor- en nadelen. Het 
protocol van de British Hypertension Society (BHS) uit 1993 en het protocol 
van de Association for the Advancement of Medical Instrumentation (AAMI) 
uit 1992 worden het meest gebruikt. In hoofdstuk 2 worden een aantal 
aspecten van bovengenoemde protocollen nader toegelicht en bekritiseerd. 
De uit te voeren analyse blijkt niet eenduidig omschreven te zijn in het BHS-
protocol. Dit kan leiden tot verschillen in de gerapporteerde nauwkeurigheid 
voor dezelfde oscillometrische bloeddrukmeters (hoofdstuk 2.1). In 2002 
werd het International Protocol (IP) gepubliceerd met als doel de validatie 
te vereenvoudigen. In hoofdstuk 2.2 worden de voor- en nadelen van het 
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IP belicht. Het IP maakt in tegenstelling tot het BHS-protocol geen gebruik 
van een graderingsysteem (van uitstekend (A) tot zeer slecht (D)) om de 
nauwkeurigheid van een bloeddrukmeter aan te geven. Het graderingsysteem 
is in het IP vervangen door een slagen/falen systeem. In hoofdstuk 2.2 wordt 
toegelicht dat dit de vergelijking tussen gevalideerde apparaten bemoeilijkt 
en dat ook gegevens als het gemiddelde bloeddrukverschil en de standaard 
deviatie van de gemeten verschillen tussen testapparaat en kwikmanometer 
vermeld zouden moeten worden.
De Welch Allyn Vital Signs Monitor 52000, een apparaat dat de bloeddruk 
oscillometrisch meet aan de bovenarm, blijkt in de studie beschreven in 
hoofdstuk 2.3 de bloeddruk onnauwkeurig te meten met een graad C voor 
diastolische bloeddruk en een graad D voor systolische bloeddruk. Deze 
bloeddrukmeter werd echter ook getest door de onderzoeksgroep van Jones 
et al.1 Zij concludeerden dat de bloeddrukmeter wel nauwkeurig was met een 
graad A voor zowel diastolische als systolische bloeddruk. Redenen voor de 
gevonden verschillen worden nader toegelicht in hoofdstuk 2.3. Naast de Welch 
Allyn Vital Signs Monitor werd een tweede bloeddrukmeter door ons getest. 
De resultaten staan beschreven in hoofdstuk 2.4. Het blijkt dat ook de Omron 
RX-M, een apparaat dat de bloeddruk oscillometrisch meet aan de pols, een 
onnauwkeurig apparaat is.
In de literatuur wordt steevast vermeld dat de nauwkeurigheid van 
oscillometrische  bloeddrukmeters afneemt bij hogere bloeddrukwaarden. Of 
dit inderdaad het geval is werd nader onderzocht in het onderzoek beschreven 
in hoofdstuk 2.5. De nauwkeurigheid van de bloeddrukmeters blijkt inderdaad 
voor de meeste apparaten af te nemen bij hogere bloeddrukken. In hoofdstuk 
2.5 wordt nader ingegaan op de vraag of dit mogelijk een schijnbare afname 
betreft.  
Dankzij de ontwikkeling van automatische bloeddrukmeters is het gemakkelijker 
geworden voor patiënten om zelf in de thuissituatie de bloeddruk te meten. 
Bloeddrukmeters zijn tegenwoordig zeer gemakkelijk aan te schaffen, 
bijvoorbeeld via het Internet. In de hoofdstukken 3.1 en 3.2 wordt nader 
ingegaan op aspecten die bij thuisbloeddrukmetingen van belang zijn. Daarnaast 
worden adviezen gegeven over welke apparaten het beste door de patiënt 
kunnen worden gebruikt. Hoofdstuk 3.1 betreft apparaten die de bloeddruk 
meten aan de bovenarm en hoofdstuk 3.2 betreft apparaten die de bloeddruk 
meten aan de pols.  
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Verschillende aspecten van onvoldoende therapietrouw die bij de behandeling 
van hypertensie een rol spelen worden nader toegelicht in hoofdstuk 4.1. Aan 
de hand van een aantal casus wordt benadrukt dat bij elke patiënt waarbij de 
bloeddruk onvoldoende reageert op de gestarte antihypertensieve medicatie 
moet worden overwogen of de patiënt wel voldoende therapietrouw is. Helaas 
ontbreekt tot nu toe een betrouwbare methode om de mate van therapietrouw 
te meten. Bij elektronische monitoring met behulp van zogenaamde Medication 
Event Monitoring System (MEMS) potjes wordt de datum en het tijdstip van 
elke opening van het medicatiepotje geregistreerd en op de PC uitgelezen. De 
registratie hiervan garandeert echter niet dat de tabletten daadwerkelijk zijn 
ingenomen. Indien een marker wordt toegevoegd aan een geneesmiddel en 
deze marker vervolgens wordt bepaald in het bloed van de patient, bestaat er 
wel controle op de inname. In hoofdstuk 4.2 worden de resultaten beschreven 
van onderzoek naar het gebruik van bromide als marker voor de mate van 
therapietrouw bij 24 gezonde vrijwilligers. De farmacokinetische eigenschappen 
van bromide worden nader toegelicht. De halfwaardetijd van bromide blijkt 
ongeveer 11 dagen te zijn waardoor het geschikt is als marker voor de mate van 
therapietrouw over een langere periode. De klinische toepassing van bromide 
als marker werd onderzocht in een groep van 30 patiënten met hypertensie 
(hoofdstuk 4.3). Dertig milligram kaliumbromide werd toegevoegd aan een 
combinatiepreparaat, bestaande uit een angiotensine converterend enzym 
remmer en een calciumantagonist. De mate van therapietrouw gemeten met 
behulp van bromide kwam goed overeen met die gemeten met MEMS potjes. De 
therapietrouw van de geïncludeerde patiënten was in deze studie echter zeer 
hoog. Hierdoor kon de relatie tussen de mate van therapietrouw en de reactie 
op de antihypertensieve medicatie niet worden nagegaan. 
Het meten van de therapietrouw met behulp van bromide heeft een aantal 
nadelen. Geneesmiddelen waaraan kaliumbromide is toegevoegd zijn niet 
commercieel voorhanden. Voor de bepaling van bromide is een bloedafname 
nodig. Verder is de bepaling vrij arbeidsintensief, tijdrovend en kostbaar. 
Desalniettemin kan de methode worden toegepast voor het objectief meten en 
vervolgen van de mate van therapietrouw in bepaalde probleemgevallen.
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Hierbij wil ik iedereen die direct of indirect een bijdrage heeft geleverd aan de 
totstandkoming van dit proefschrift hartelijk danken.
In het bijzonder wil ik noemen:
Prof. dr. Th. Thien, mijn promotor van het eerste uur. Beste Theo, zonder jou 
zou dit proefschrift er niet geweest zijn. Jouw enthousiasme, gedrevenheid, 
eerlijkheid en openheid hebben mij vanaf het begin gegrepen. Dat een iets 
langer dan drie maanden durende wetenschappelijke stage uiteindelijk zou 
uitgroeien tot een promotie had ik nooit durven denken. Je wist me door de 
jaren heen overal te vinden (Zevenaar, Nijmegen, Nieuwegein, Amersfoort) en 
bleef altijd optimistisch. Je bent een wetenschapper pur sang. Ik heb veel van 
je geleerd en vind het een eer één van je laatste promovendi te zijn nu je met 
emeritaat bent gegaan. 
Prof. dr. J.W.M. Lenders. Beste Jacques, als promoter ben je in de tweede helft 
van dit proefschrift een belangrijke rol gaan spelen. Artikelen waar Theo en ik 
soms al enige tijd mee aan het stoeien waren, werden door jouw zienswijze 
verder verbeterd. Ik dank je voor de energie en tijd die je hebt willen steken 
in dit proefschrift.
Alle leden van de manuscript commissie, prof. dr. F.W.A. Verheugt, prof. dr. 
J.F.M. Wetzels en dr. W.J.W. Bos, wil ik hartelijk danken voor het kritisch 
doorlezen van het manuscript.
Dr. S.H.M. van Uum. Beste Stan, hartelijk dank voor je substantiële en onmisbare 
aandeel in dit proefschrift. Het kan haast geen toeval zijn dat jij nu werkzaam 
bent als internist in Canada in de buurt van dezelfde universiteit waar een 
groot deel van het onderzoek naar therapietrouw heeft plaatsgevonden.
Dr. D.W. Swinkels en prof. dr. F.G.M. Russel. Beste Dorine en Frans, hartelijk 
dank voor jullie bijdrage aan het artikel over de bromide bepalingen bij 
vrijwilligers.
Carlijn de Maat wil ik hartelijk danken voor het helpen uitvoeren van talloze 
bloeddrukmetingen en het rekruteren van vrijwilligers bij het testen van de 
Welch Allyn Vital Signs Monitor.
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Bünyamin Aslan wil ik danken voor zijn werk bij het testen van de Omron RX-M.
Wim Lemmens, hartelijk dank voor het 'tot leven' brengen van de database met 
gegevens uit de Tarka studie. 
Alle patiënten en vrijwilligers die geheel belangeloos deelnamen aan het 
onderzoek beschreven in dit proefschrift, hartelijk dank!
Alle leden en oud-leden van de maatschap cardiologie van het St. Antonius 
Ziekenhuis te Nieuwegein wil ik bedanken voor hun interesse naar de vorderingen 
van de promotie en de tot nu toe genoten opleiding. 
Alle (oud-)collega’s van het Canisius-Wilhelmina Ziekenhuis, het Meander 
Medisch Centrum en het St. Antonius Ziekenhuis wil ik bedanken voor hun 
gezelligheid, in het bijzonder Hendrik-Jan Dieker uit Nijmegen. Beste Hendrik-
Jan, bedankt voor je vriendschap, ontstaan tijdens onze eerste maanden in het 
CWZ. Succes met de laatste loodjes van jouw promotie.
Menno Dijkhuizen. Beste Menno, jij wist altijd feilloos mijn herhaaldelijk 
weigerende computer te reanimeren. Hartelijk dank!
Irene Verbaan. Beste Irene, inmiddels is dit alweer je derde boekje. Met je 
relaxte houding maak je de vaak stressvolle laatste stappen naar de promotie 
tot een feest.
Maarten Rookmaaker en Marieke Yo. Beste Maarten en Marieke, binnenkort 
familie Rookmaaker-Yo. Ik wil jullie hartelijk danken voor jullie vriendschap. 
Maarten, met je lichte(?) vorm van manie wist je me altijd in de goede richting 
te leiden op momenten dat ik dat blijkbaar even nodig had.
John en Anjo Tabbers. Dat ik de eerste woorden van dit dankwoord typ achter 
de computer in jullie mooie huis en dito tuin in Waalre zegt genoeg. Hartelijk 
dank voor jullie steun en liefde.
René en Anne Driessen. Ik geniet altijd erg van onze dineetjes, afwisselend in 
Oss en Nieuwegein. Hartelijk dank voor jullie gezelligheid.
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Annemieke en Evelien. Mijn twee lieve zussen en bovendien paranimfen. 
Dat jullie ook geneeskunde zijn gaan studeren zal wel een genetische 'tik' 
zijn geweest. Gelukkig hebben we tot nu toe elk een ander orgaan kunnen 
kiezen…
Mijn ouders, lieve pappa en mamma. Bedankt voor jullie steun en stimulatie. 
Dit proefschrift is niet voor niets aan jullie opgedragen.
En tenslotte lieve Frederieke. Met jou aan mijn zijde vliegt de tijd. Bedankt 
voor je geduld als er weer eens aan het proefschrift moest worden gewerkt, je 
onvoorwaardelijke steun en liefde.
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De auteur van dit proefschrift werd geboren op 1 oktober 1975 te Haarlem. Na 
het volgen van het VWO van 1988 tot 1994 aan het Liemers College te Zevenaar, 
begon hij in 1994 met de studie geneeskunde aan de Katholieke Universiteit 
te Nijmegen. Het artsexamen werd behaald in 2000. Aan het einde van zijn 
co-schappen werd tijdens een wetenschappelijke stage bij Prof. dr. Th. Thien 
de grondslag gelegd voor dit proefschrift. Na enkele maanden als poortarts te 
hebben gewerkt in het Streekziekenhuis te Zevenaar, was hij vanaf december 
2000 werkzaam als AGNIO cardiologie in het Canisius-Wilhelmina Ziekenhuis 
(opleider Dr. T. Hooghoudt) en vanaf eind 2001 in het St. Antonius Ziekenhuis te 
Nieuwegein. In oktober 2002 begon hij met de opleiding tot cardioloog (opleider 
dr. W. Jaarsma) en startte in het Meander Medisch Centrum te Amersfoort met 
de vooropleiding Interne Geneeskunde (opleider dr. A. van de Wiel). Vanaf 
oktober 2004 is hij wederom werkzaam in het St. Antonius Ziekenhuis voor het 
vervolg van de cardiologie opleiding. Deze zal in 2008 worden afgerond.
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